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ABSTRACT 
Failure in receiving a booster for specific vaccines contributes to incomplete 
seroconversion, particularly in the developing world. Single injection vaccine 
technology could potentially be a solution such that health care personnel would not 
need to meet patients multiple times at designated points in time thereafter. The main 
challenge for single injection vaccine systems to date is controlling the stability of the 
antigen. to maintain the antigenic protein structure while in the physiological 
environment. We engineered a novel phase-separating microbubble technology which 
could function as an injectable depot which we hypothesize will enable us to control the 
microenvironment of the antigen for the durations required, in addition to controlling the 
antigen release time. 
We have successfully accomplished the following Main Specific Aims and sub-
aims:  
Main Specific Aim 1: Synthesize polymers for microbubbles formation and Engineer 
methods for stabilizing Microbubbles: 
1A: Synthesize PCL and PLGA library at different molecular weights and 
characterizing the polymers 
1B:  Synthesize acrylate polymers for microbubbles 
1C: Engineer stable microbubble through UV cure and lyophilization        
1D: Engineering the microbubbles to be stationary for maintaining sphere shape during 
the curing process and the inject of the cargo 
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1E: Engineering the cargo to be stationary within the polymeric microbubble to 
maximize the release time 
1F: Quantify the diameter of the microbubble by varying syringe pump rate and 
comparing diameter pre- and post-lyophilization 
1G: Quantify the angle of the micromotor for injecting cargo into the center of the 
microbubbles 
1H: Engineer a self-contained lyophilization-capable system for the microbubbles 
Main Specific Aim 2: Engineering cargo release time of the microbubbles: 
2A: Quantify how different molecular weights of PCL affect release time of the 
microbubbles 
2C: Quantify how varying the microbubbles’ thickness of the shell controls the release 
time 
Main Specific Aim 3: Quantify stability of HIV and Hepatitis B antigens: 
3A: Quantify how the HIV gp120/41 and HBsAg ayw antigens are stable in time in an 
aqueous environment versus in a cryo-protectant context at varying temperatures 
Our novel phase-separating technology which can form microbubble vaccine 
depots is a promising method to alleviate stability issues which hinders the single 
injection vaccine field. Enhancement of antigen stability in the microbubbles will be 
determined in future work. 
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NOMENCLATURE 
1H NMR Proton NMR 
3D Three-dimensional 
AIDS Acquired Immunodeficiency Syndrome 
APC Antigen Presenting Cell 
B/CS Bryan/College Station 
bNAB broadly Neutralizing Antibody 
BSA Bovine Serum Albumin 
CCR5 C-C Receptor Type 5 
CF Correction Factor 
CMC Carboxymethyl Cellulose 
CpG Cytosine-phophodiester bond-guanine 
CPP Cell-penetrating Peptides 
CS Chitosan 
CTL Cytotoxic T Lymphocyte 
DCM Dichloromethane 
DI Deionized 
DMPA 2,2-Dimethoxy-2-Phenylacetophonone 
DMSO Dimethyl Sulfoxide 
DNA Deoxyribonucleic Acid 
DSC Differential Scanning Calorimetry 
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DTP3 Three-dose Diphtheria-Tetanus-Pertussis 
DTPA Diethylenetriaminepentaacetic Acid 
DTS DNA Targeting Sequence 
EDTA Ethylene Diamine Tetra-acetic Acid 
ELISA Enzyme-Linked Immunosorbent Assay 
EPO Eudragit® E PO 
FDA Food and Drug Administration 
G Glycolide monomer 
gp120 Glycoprotein 120 kDa 
gp41 Glycoprotein 41 kDa 
HBsAg Hepatitis B Surface Agent 
HBV Hepatitis B Virus 
HEMA Hydroxyethyl Methacrylate 
HIV Human Immunodeficiency Virus 
HIV-1 HIV subtype 1 
HIV-2 HIV subtype 2 
HRP Horseradish Peroxidase 
HSUS Humane Society of the United States 
ICMV Interbilayer-crosslinked multilamellar lipid vesicles 
IFN Interferon 
Ig Immunoglobulin 
IL Interleukin 
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IPV Inactivated Poliovirus Vaccine 
IV Inactivated Vaccine 
L Lactide monomer 
LAV Live Attenuated Vaccine 
Lbl Layer-by-layer 
M Million 
MHC I/II Major Histocompatibility Complex (class I/class II) 
MP Microparticle 
mPEG Methoxypolyethylene Glycol 
mRNA Messenger RNA 
MW Molecular Weight 
NMR Nuclear Magnetic Resonance Spectroscopy 
NP Nanoparticle 
OPV Oral poliovirus vaccine;  
OVA Ovalbumin;  
P Pressure 
P(A) polyadenylation  
PAA polyacrylic acid 
PAMP Pathogen-associated Molecular Pattern 
PBAE Poly(β-amino ester) 
PCL Poly(𝜀-caprolactone) 
PCLDA PCL Diacrylate 
  x 
PCLTA PCL Triacrylate 
PCPH Poly[(1,6-bis-carboxyphenoxy) hexane] 
PEG Polyethylene Glycol 
PEI Polyethylamine Imine 
PLGA Poly(lactic-co-glycolic acid) 
PLLA Poly(L-lactic acid) 
PMMA Poly(methyl methacrylate); 
ppm Part per million 
PNA Peptide Nucleic Acid 
PVA Polyvinyl Alcohol  
RNA Ribonucleic Acid 
SEM Scanning Electron Microscopy 
SO Tin(II) 2-ethylhexanoate  
SV40 Simian Virus 40 
T Time 
TCEP Tris-(2-carboxyethyl)phosphine 
TCR T Cell Receptor 
TEA Trimethylamine 
TEGDMA Triethylene Glycol Dimethacrylate 
TGF Transforming Growth Factor 
Th Helper T Cell 
TLR Toll-like Receptor 
xi 
TMB Tetramethylbezidine 
TMC N-trimethyl Chitosan Chloride 
TNF Tumor Necrosis Factor 
Tg Glass transition temperature 
Tm Melting temperature 
TVA Tennessee Valley Authority 
TxDOT Texas Department of Transportation 
UV Ultraviolet 
VLP Virus-like particle 
WHO World Health Organization 
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1 INTRODUCTION* 
Infectious diseases are one of the main causes of death globally. For instance, lower 
respiratory infections are the third biggest killer (3.19 M deaths) following by ischemic 
heart disease (8.46 M deaths) and stroke (6.24 M deaths) in 2015 (Figure 1) [1]. 
Initially, vaccines were developed as a preventive treatment against infectious diseases 
but now vaccines are being used for therapeutic approaches (e.g. cancer therapy). Since 
the first vaccine against smallpox was developed by Edward Jenner, scientist eradicated 
numerous infectious diseases and the overall death rate has decreased continuously from 
0.8% to 0.046% for the last 114 years.  
Even though many vaccines were developed and they reduced the mortality rate due 
to infectious disease, death from several infectious diseases increased such as AIDS and 
vector-borne diseases [1]. This problem is more serious in developing countries. From 
2015 to 2017, the 68 poorest countries presented an average coverage rate of 80% for the 
3 doses of diphtheria-tetanus-pertussis (DTP3) (Figure 2). This means that 19.4 M 
children cannot receive DTP3 nowadays [2]. Another example is Hepatitis B. In the 
western pacific countries, the at-birth coverage rate for HBV was 79% while in the 
African region it was 11% [3]. The reason is that there are many barriers to increasing 
__________________________ 
*Adapted with permission from: Dutta, et al. J. Mater. Chem. B. 2017, 5, 4487–4498. Copyright © 2017
RSC; Berkland, et al. J. Control. Release. 2004, 96, 101–111. Copyright © 2017 Elsevier;  Adapted from: 
McHugh, et al. Science. 2017, 357, 1138–1142. Copyright © 2017 AAAS. 
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Figure 1 Top 10 causes of death globally published in 2015 by the WHO. Reprinted 
from [1]
Figure 2 Timeline for the global DTP3 vaccine coverage published in 2015 by 
WHO. Adapted from [2]
Ischaemic heart disease 
Stroke
Lower respiratory 
infections
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the vaccine coverage rate in developing countries. 
One of the main barriers is their poor health care system. According to the WHO, 
2-3 million people can be saved from death by completing every dose of vaccination. 
However, most African countries and India have 1 doctor per 2000 people, in 2010 [4]. 
Therefore, visiting medical facilities every time to complete a vaccination is not easy for 
patients and the cost for every dosage is also a burden for them. 
Another reason for poor vaccine coverage is issues with functionality because of 
the instability of antigens. For amino acid-based and protein-based vaccines, thermo-
instability and hydrolysis greatly diminishes the vaccines efficacy. Proteins are exposed 
to harsh temperatures during poor transportation and storage conditions.  Transportation 
systems in the developing world generally have an incomplete cold chain, causing 
antigen instability during transportation. A reasonable approach to tackle a number of 
these issues is the single injection vaccine based on non-viral polymeric delivery 
systems [5-7]. Through this single injection vaccine, multiple doses can be administered 
at once. Therefore, single injection vaccines reduce or eliminate the need for multiple 
visits to a medical facility. Furthermore, the burden of cost could be potentially 
mitigated with fewer visits to medical facilities for both the people to be vaccinated, as 
well as the medical personnel involved in the vaccination itself. The main challenges for 
single injection vaccines are engineering the release kinetics and the antigen stability. 
However, stabilizing the antigen is far more challenging than controlling the release 
kinetics over the durations needed for completing vaccination.   
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It is highly likely that novel release profiles may be more efficient than what is 
commonly done for a type of vaccine. For example, although 0, 1, and 6 months may be 
used for a vaccine, a limited number of permutations of the vaccine schedule has been 
tested.  
For a single injection vaccine, every dosage that will be exposed to the patient’s 
immune system is injected at the same time. Each dosage should be released at each 
expected date. For instance, a hepatitis B vaccine should release the second dosage and 
the third dosage at 1 month and 6 months from the injection, respectively. Also, the 
second and third antigen exposures should be in a conformation that will generate 
neutralizing antibodies against the antigen wild types.  A great deal of research has 
shown successful results in controlling release kinetics, but they have difficulty in 
maintaining antigen stability over the durations required for complete seroconversion.  
Although a number of research laboratories use traditional microparticles, there 
are a number of drawbacks such as loss of antigen stability due to contact with organic 
solvent during the precipitation processes. Furthermore, an antigen can lose its 
functionality due to ultrasound during the emulsification.  The microparticles have an 
extremely high surface area of aqueous phase in contact with organic solvent for double-
emulsion processes.  
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Figure 3 State-of-the-art for polymeric delivery systems (A) PLGA/PLLA 
microbubble confocal image of the short solvent evaporation group (B) 
PLGA/PLLA microbubble release profile. SEM images of (C) laser scanning 
confocal micrographs of PLGA/PCPH double-walled polymer microspheres (D) a 
single particle, (E) the core of a particle, and (F) a sealed particle. (G) A cross 
section of a single particle. Reprinted from [5, 8, 9].
In the study presented by Dutta, et al. using PLGA/poly(L-lactic acid) (PLLA) 
microparticles, protein is able to be distributed to varying degrees more towards the 
center (Figure 3A) [5] of the microparticle using combinations of long and short solvent 
evaporation times, as well as in the presence or absence of ethanol.  Such formulations 
can result in a burst release profile (Figure 3B). Berkland, et al. produced double-walled 
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microparticles using PLGA and poly[(1,6-bis-carboxyphenoxy) hexane] (PCPH) 
(Figure 3C) [9]. Release profiles was controlled by controlling mass ratio of PCPH:PLG 
and the shell thickness. However, in both of these studies, there was an extremely high 
surface area where the protein was in direct contact with the organic solvent, denaturing 
the protein.  
McHugh, et al. synthesized a PLGA-based vaccine depot on the order of a few 
hundred microns using a microfabrication technique involving photolithography to form 
a poly(dimethyl siloxane) (PDMS) mold which is then used as yet another mold for 
forming the micron-scale PLGA depots. A picoliter dispensing technology was used to 
fill the depots. A mask aligner was then used to align the caps for the micron-sized 
depots which had been filled with a cargo of interest (Figure 3D-G). Such 
microparticles allowed a highly controlled bolus release by varying the PLGA 
MOLECULAR WEIGHT and L:D monomer ratio [8], but the failure rates of capping 
the depots were high, which made predicting when they would burst difficult. The 
sealing of the depots was successful along a continuum, causing the burst release to 
occur anywhere from time 0 (improperly capped and easily apparent) up until when the 
depot was designed to be released. Screening for the depots which would release after 
time zero and prematurely is currently a challenge this technology faces. This 
technology could be incredibly impactful if the issue of predicting which particle will 
prematurely release is rectified.  
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Our proposed microbubbles will have no sealing of caps, homogenization or 
sonication, and a greatly minimized surface contact area of antigen directly in contact 
with organic solvent. 
Figure 4 Concept of the microbubble fabrication system. Polymer and drug are 
injected using micromotors. Microbubble is supported into 10% CMC matrix, 
which also prevents drug leakage after injection within the microbubble.  
In this work, we suggest a microbubble as a novel platform as a vaccine delivery 
carrier (Figure 4). This microbubble can reduce many downsides of emulsification and 
thermal treatment for sealing. First, our microbubbles can stabilize antigens because they 
do not need ultrasound and they do not have such large surface areas in contact with 
organic solvent. Our microbubbles will also lead to release kinetics that is a bolus 
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instead of sustained antigen release which is a common release profile when using 
traditional microparticles. Sustained release is known to cause T cell anergy. Causing T 
cell anergy may be useful for certain applications of anti-autoimmune disease 
formulations, however.   
In addition, in this thesis, I describe the development of a phase-separating 
microbubble as a novel vaccine depot. Engineering the release time of the microbubble is 
crucial for the development of a single injection vaccine technology (Aim 1). Section 3.1 
entails the synthesis of PLGA and PCL, and section 3.2 describes the development of 
microbubbles using a blend of poly(𝜀-caprolactone) (PCL) and PCL triacrylate (PCLTA). 
Section 3.3 shows how lyophilization improves stability of the microbubble post UV 
curing. Also, section 3.4 describes how the microbubble maintains its shape and can be 
suspended during the formation and injection processes. Section 3.5 entails how to 
engineer the cargo to stay centered within the microbubble. Section 3.6 quantifies how the 
diameter of the microbubble varies as a function of the syringe pump rate and also how 
pre- and post-lyophilization affects the diameter. Section 3.7 quantifies the angle of the 
micromotor necessary for injecting cargo within the microbubbles.  Section 3.8 describes 
engineering a self-contained system which will enable lyophilization of the microbubbles. 
Main Specific Aim 2 entails engineering the release time of the microbubbles. 
Section 4.1 quantifies how different molecular weights of PCL affect release times of the 
microbubbles. Section 4.2 quantifies how varying the microbubbles’ thickness of the 
shell controls the release time. 
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Section 5 quantifies stability of HIV and Hepatitis B antigens in a non-
microbubble context as a positive control for the antigen protection within the 
microbubble (ongoing work). Section 5 describes how the HIV gp120/41 and HBsAg 
ayw antigens are stable in time in an aqueous environment versus in a cryo-protectant 
context at varying temperatures. 
Section 6 entails conclusions and future direction of this work. Finally, section 7 
provides a thorough review of literature regarding amino acid- and protein-based 
vaccines for anti-infectious disease applications. 
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2 BACKGROUND* 
2.1 CHALLENGES IN VACCINE COVERAGE 
The World Health Organization (WHO) estimated that 19.5 M infants annually 
cannot receive adequate vaccination throughout the world [2]. Two of the biggest 
impediments which inhibit improving vaccination coverage rates is the poor medical 
facilities and general medical welfare found in the developing countries. Statistics show 
that the people-to-doctor ratio of African countries is less than 3333 to 1; whereas, more 
than 110 countries have at least one doctor per 1000 people. Such statistics become 
increasingly worse when multiple doses, long administration regimens, and cold chain 
distribution are required. 
2.2 HEPATITIS B AND STATE OF THE ART FOR VACCINES 
The hepatitis B virus (HBV) and induces a liver infection, which contributes to 
diseases such as cirrhosis or hepatocellular carcinoma [10]. More than 248 million 
people have chronic hepatitis B disease globally, and 25% of those who are infected with 
HBV in infancy have a higher risk of developing the primary liver cancer or cirrhosis as  
__________________________ 
*Adapted with permission from: Taluja, et al. J. Mater. Chem. 2007, 17, 4002, Copyright © 2017 RSC.
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adults [11]. According to the statistics of the WHO, several African countries such as 
Equatorial Guinea, Central African Republic, and Guinea have a low coverage rate of 
Hepatitis B vaccine, therefore the mortality rate of babies who is 0 year old is 2-5 times 
higher than that in other African countries [3]. 
HBsAg constitutes four serotypes: ayw, ayr, adw, and adr, which is geographically 
dependent. For example, most countries on the American continent have the adw 
serotype, and most African countries have the ayw serotype. High mortality countries in 
the north of the southern Africa countries, such as Angola, Vanuatu, and Chad usually 
involve the ayw serotype [12]. However, current commercialized HBsAg-based vaccines 
(e.g. Recombivax HB® and Engerix-B®) are for the immunization against the adw 
serotype, which is common in the Americas. We will be developing a vaccine depot 
system for the ayw serotype, which will dually function as a proof-of-concept for such a 
delivery system that would be far more convenient in the developed world as well. 
Vaccine schedules for the hepatitis B vaccine (HBsAg) for babies are currently at 
0, 1, and 6-month bolus injections, starting at birth [3]. However, the completion of all 
requisite inoculations is difficult for poor medical facilities. A study about the coverage 
of vaccination against hepatitis B in the rural population of China showed that people 
with lower incomes tend to present with higher rates of ineffective vaccination [13]. If 
all the vaccines in the schedule could be delivered in a single injection vaccine 
containing three microbubbles with different releasing time points, the vaccine coverage 
rate would increase significantly. 
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Projections for 2015-2030 indicate a reduction of 90% of new chronic hepatitis B 
cases and a 65% decrease in the mortality rate, once the vaccine coverage achieves 90% 
of infants, 80% of neonates [14]. 
2.3 HIV AND STATE OF THE ART FOR VACCINES 
HIV can cause AIDS, and currently there is no commercially available 
prophylactic therapy. Globally, 36.7 M people (2015), and 1.2 M people in the United 
States are living with HIV, and this number is increasing annually. Fourteen percent of 
the infected population are unaware of their condition, which unintentionally exposes 
uninfected people. 
In regard to subtypes, HIV-1 is more pathogenic than the HIV-2; both are capable 
of infecting T cells. However, only HIV-1 can escape the innate immune system 
recognition which is primarily accomplished by avoiding dendritic cells. HIV-1 presents 
a high evolution rate and wide genetic variability, which are challenges to the 
development of antiretroviral drugs and vaccines [15, 16]. 
It is crucial to choose adequately conserved antigens for subunit vaccines. Thus, 
viral capsid glycoprotein (gp) molecules, which are highly conserved sequences, may 
provide such reliability required for developing vaccines [17, 18]. There are many 
clinical trials employing the gp120 and gp41 as an HIV-1 vaccine but to date there has 
not been satisfactory seroconversion for adequate protection [15]. Furthermore, 
developing broadly neutralizing antibodies against HIV vaccine is a highly sought after 
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objective [19], in addition to developing stable antigens to enable transportation of the 
vaccine itself to enhance coverage [20]. 
2.4 SINGLE INJECTION VACCINES 
Generally, live attenuated vaccines are lyophilized in order to enhance stability. 
The storage and transportation temperature should remain between 2 ºC to 8 ºC, which is 
the same temperature range recommended to store and distribute inactivated and subunit 
vaccines [21, 22]. Temperature oscillation and long-term exposure to out-of-range 
temperatures can reduce the antigen functionality of a recombinant protein vaccine (i.e. 
HBsAg ayw for hepatitis B and gp120/gp41 for HIV-1). Enhanced antigen stability in 
ambient temperatures and single injection technology could potentially enable improved 
immunization coverage for more people. For developing countries, a thermostable 
vaccine would be able to bypass cold chain shipment issues. For developed countries, 
thermostable single injection vaccines will bring a convenient will bring a convenient 
alternative to avoid several visits to healthcare centers. 
Current studies involving single injection vaccines struggle to control antigen 
stability over the duration required for boosting. Nano/microparticles based on 
biocompatible and biodegradable polymers have been widely investigated for bolus, 
pulsatile, and sustained release applications using a number of different polymers (e.g. 
PLGA, PCL) [20].  
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There are several studies focused on enhancing the thermal and long-term antigen 
encapsulated stability (i.e. up to 12 months within carriers for specific antigens which 
are considered relatively easier to stabilize) [23]. This has been mainly accomplished by 
various freeze-drying procedures in conjunction with the use of cryo- or lyoprotectants 
that improve vaccine shelf-life and stability during transportation in the presence or in 
the absence of complete cold chain distribution capabilities.  
However, these studies did not focus on preserving the antigenicity after 
administration for long-term self-boosting delivery [24, 25]. It is necessary to (1) ensure 
the pH is not damagingly low for the antigen; (2) optimize the antigen/cryo-protectant 
ratio to preserve precious antigen cargo space within the depot; (3) optimize the 
lyophilization to properly remove water to the extent necessary; and, lastly, (4) ensure 
the particles auto-boost at the expected times. 
2.5 UTILITY OF PLGA FOR DRUG DELIVERY SYSTEMS 
Poly(lactic-co-glycolic acid) (PLGA) is a biodegradable and relatively 
biocompatible copolymer which has been approved for clinical use for specific 
applications by the US Food and Drug Administration (FDA) and the European 
Medicines Agency. Successful encapsulation in PLGA nanoparticle/microparticle 
(NP/MP) depot as injectable delivery systems was reported for anticancer drugs [26], 
peptides/proteins [27], DNA [28], and RNA [29]. The hydrolytic degradation of the 
PLGA backbone produces lactic and glycolic acids (Figure 5), and which can be 
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biologically incorporated within the body, causing minimal damage [30]. Loss of 
conformation or denaturation of peptides/proteins encapsulated in PLGA due to the 
acidic degradation of PLGA may be controlled by using internal buffers and neutralizing 
reagents [25], or blending PLGA with pH-sensitive polymers [31].  
Figure 5 De-esterification of PLGA backbone in an aqueous environment 
producing lactic acid, glycolic acid, acidic oligomers, and free protons which self-
catalyze the degradation further and can cause issues with pH regulation for 
antigen stability. Adapted from [32]
Currently, there is an extensive variety of PLGA-based biomedical technologies, 
such as orthopedic implants [33], bone regenerative scaffolds [34], surgical devices [35], 
and drug delivery systems [36].  This versatility is due to PLGA’s highly tunable 
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chemical properties. The hydrophilicity and hydrophobicity of PLGA can be controlled 
by increasing the glycolide and lactide monomer ratios, respectively, or by combining 
with other monomers in a conjugated fashion. For instance, mPEG 
(methoxypolyethylene glycol) can be added to PLGA in a diblock copolymer manner to 
control the hydrophilic/hydrophobic balance [37]. However, inflammatory responses 
have been reported as a side effect of PLGA implants due to the long-term acidic 
degradation 45 and should be carefully assessed during the development of such 
polymer-based applications to ensure all safety requirements are appropriately satisfied. 
In 2016, there were 15 FDA-approved drugs for the US market using PLGA as a 
delivery platform [38]. In the past ten years, several intrinsic drawbacks of PLGA have 
been studied [39]. The PLGA cell-recognition capacity and susceptibility to opsonization 
can be potentially mitigated by surface modification of PLGA NPs/MPs [40-42]. Also, 
surface modifications may be used to modify the kinetics of cellular uptake by endocytic 
pathways [6].  
Thermostabilization of PLGA-encapsulated drugs for storage and transportation 
purposes can be achieved by a freeze-drying technique and the use of lyo-/cryo-
protectants such as trehalose [43].  
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2.6 UTILITY OF PCL FOR DRUG DELIVERY SYSTEMS 
Poly(𝜀-caprolactone) (PCL) is a biodegradable and biocompatible polymer used in 
several FDA-approved biomedical devices. The PCL structure is hydrophobic in nature 
and contains semi-crystalline domains, and has relatively low glass transition 
temperature (-60 ºC for a MW 65K) [44]. The PCL`s long degradation rate (up to a year) 
[45] has been used for bone regeneration applications [46], three-dimensional (3D) 
tissue scaffolds [44], 3D-printed resorbable membranes for bone regeneration and bone 
integration [47], and drug delivery systems intended for long durations[48].  
PCL is commonly conjugated with another polymer to produce multi-block 
copolymers in order to obtain specific properties. For instance, PCL/PLGA conjugates 
are studied in different compositions. Block copolymers of PCL and PLGA (i.e. tri-block 
PLGA-PCL-PLGA) phase separate and results in a flexible material at room temperature 
because the temperature is above PCL’s Tg. Because room temperature is generally 
below PLGA’s Tg, PLGA is more glass-like state and the resulting tri-block PLGA-PCL-
PLGA is similar to a rubbery material where there are domains which are able to move 
translationally while other domains do not. Chou, et al. employed PCL/PLGA (20:80) to 
produce fibers for drug delivery. Such composition allowed differential drug partitioning 
between the PCL and PLGA phases and the PLGA promoted faster drug release [49]. 
18 
3 SYNTHESIZE POLYMERS FOR MICROBUBBLE FORMATION AND 
ENGINEER METHODS FOR STABILIZING MICROBUBBLES* 
3.1 SYNTHESIZE PCL AND PLGA LIBRARY AT DIFFERENT 
MOLECULAR WEIGHTS AND CHARACTERIZING THE POLYMERS 
3.1.1 Introduction 
Certain vaccines require multi-dose regimens to enable complete seroconversion. 
According to the Advisory Committee on Immunization Practices, hepatitis B requires 
an immunization schedule of 0, 1, 6-month [50]. A multiple-dose vaccine regimen can 
be administered in a single vaccine administration, and there is no need for a second or 
third visit to a medical facility to receive those doses. From a kinetic engineering point 
of view, it is necessary to control the (i) long-term release (i.e. months) and ensure a (ii) 
bolus release to prevent T cell anergy.  
We hypothesized that different molecular weights of polymers would have 
different release kinetics because longer chains of higher molecular weight polymer can 
entrap cargo longer due to a greater extent of hydrolysis required. In order to assess how 
__________________________ 
*Adapted with permission from: Kweon, et al. Biomaterials. 2003, 24, 801-8, Copyright © 2017 Elsevier;
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molecular weight controlled the releases kinetics of PLGA and PCL, a low, medium, and 
high molecular weight of each were synthesized initially. Because of PCL’s is more 
hydrophobic in comparison to PLGA due to the 5 carbons between each of the ester 
groups, we hypothesized that PCL would take more time to release than PLGA because 
erosion by aqueous environments is faster in PLGA. The dynamic viscosity, glass 
transition temperature (Tg), and NMR of synthesized polymers were characterized. 
3.1.2 Materials and Methods 
3.1.2.1 Materials 
1-dodecanol (Acros organics) was used for the terminating end group for PLGA. 
Tin(II) 2-ethylhexanoate (96% SO) (Alfa Aesar) was used as a catalyst. Chloroform 
(Fisher Chemical) was used for the solvent, and anhydrous ethyl ether (Fisher Chemical) 
was used for purification purposes. ɛ-caprolactone (Alfa Aesar) was the main monomer 
used for PCL synthesis. 1,4-Dioxane-2,5-dione (Alfa Aesar) and DL-Lactide were the 
main monomers for PLGA synthesis. 
3.1.2.2 PCL synthesis 
An Oil bath was heated at 110 ºC. 1-Dodecanol was then aliquoted into a glass 
vial at varying masses to control the targeted molecular weight. For higher molecular 
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weight PCL, 0.037 g (0.045 mL) of 1-dodecanol was added to the round bottom flask. 
9.276 mL of ɛ-caprolactone was added to the flask. The ɛ-caprolactone mass was the 
same in every synthesis with varying molecular weights, but the 1-dodecanol mass was 
increased to reduce the molecular weights of PCL The molecular weight of the PCL was 
controlled by the ratio between 1-dodecanol and the repeating unit.  
Polymer PCL PLGA 
Temperature 110 ºC 140 ºC 
Monomer ε-caprolactone 1,4-Dioxane-2,5-dione and DL-Lactide 
Endcap 1-dodecanol 
Catalyst Tin(II) 2-ethylhexanoate (96% SO) 
Figure 6 PLGA and PCL synthesis. 
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The synthesis was carried out in a neat fashion and the reaction proceeded under 
an argon atmosphere. 40 µL of stock SO was added to the flask. Due to the increasing 
viscosity as the synthesis continued, the stir bar would become gradually slower and 
would stop. The round bottom flask was subsequently covered with foil and placed in 
the vacuum chamber overnight. 
For the first purification, a water bath was heated at 50 ºC in order to help solve 
the polymer into chloroform. Subsequently, a 250 mL beaker was filled with ethyl ether 
(three-fold the polymer solution that would eventually be added to the ether for crashing 
out the polymer. The ethyl ether-filled beaker was placed in a bucket, which was filled 
with ice and water to aid the precipitation of the polymer into the ether for purification 
purposes. Polymer solution was added to the ethyl ether dropwise. After the precipitated 
polymer fell to the bottom, the ethyl ether was decanted. The remaining ethyl ether was 
evaporated in the vacuum chamber, the and polymer underwent a second purification in 
a similar manner (Figure 6).   
3.1.2.3 PLGA synthesis 
L and G were allowed to warm to room temperature before opening the vial to 
avoid forming condensation on the monomer in the main container which helped not 
introducing water from the ambient atmosphere into the container. The mineral oil bath 
was heated to 140 ºC and contained a stir bar to help maintain an even distribution of 
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temperature throughout. 44.8 µL of 1-dodecanol was added to flask used for polymer 
synthesis. 5.5412 g of the L monomer and 4.4609 g of the G monomer was measured; 
this was a 50:50 monomeric L:G ratio. The weighed L and G monomers were then 
added to the flask which was placed in the secondary container with the mineral oil. The 
monomers melted together and were thoroughly mixed with another magnetic stir bar 
within the synthesis flask. The stirring was accomplished under an argon atmosphere.  
Like PCL, PLGA molecular weights were also controlled by the mass ratio of 1-
dodecanol and the mass of L and G present. As soon as the monomer was completely 
melted, 40 µL of stock SO was added to the flask. The stir bar was increasingly slowed 
down as the reaction proceeded due to the increasing viscosity of the polymer. The 
purification step was same as what was previously described above for purifying PCL. 
After the purification step, to remove the residual ether, the polymer was left in the 
vacuum chamber overnight. 
3.1.2.4 Polymer Characterization 
Each polymer was characterized via differential scanning calorimetry (DSC), 
rheometery, and nuclear magnetic resonance (NMR) spectroscopy. The dynamic 
viscosity was analyzed by DSC Q20 (TA Instruments), and the melting point of PCL and 
the glass transition of PLGA were measured using Physica MCR 301(Anton Paar). 
Mercury 300 was used for recording 1H NMR spectra. 
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3.1.3 Results and discussion 
Each polymer was prepared in three different molecular weights, using 
monomeric ratios that would theoretically target 10 kDa to 100 kDa; which we term 
Low, Med, and High MW PLGA or PCL.  
Figure 7 Average dynamic viscosity of (a) PLGA and (b) PCL using a shear rate 
which varied from 100 to 1000 (1/s). 
The dynamic viscosity of each polymer using a polymer concentration of 100 
mg/mL in chloroform was measured using a rheometer at a shear rate ranging from 100 
to 1000 1/s. For both PCL and PLGA, their dynamic viscosity increased as their 
MOLECULAR WEIGHTS increased. More specifically, the average dynamic viscosity 
of High, Med, and Low MW PCL were 13.56 mPa·s, 6.52 mPa·s, and 4.69 mPa·s when 
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using a shear rate that range from 100 to 1000 1/s. (Figure 7b). Similar behavior was 
observed for PLGA. The average dynamic viscosity of the High, Med, and Low MW 
PLGAs were 33.51 mPa·s, 20.29 mPa·s, and 3.70 mPa·s (Figure 7a). Thus, PCL had a 
narrower dynamic viscosity range when compared to PLGA.  
Figure 8 DSC curves of PCL from 45 to 65 ºC and PLGA from 20 to 70 ºC. 
Another key parameter quantified was the glass transition temperature and melting 
temperature (Tg and Tm), which was measured by DSC. The Tg for PLGA and Tm of PCL 
are presented as DSC curves in Figure 8. The Tm of PCL was identified between 50-55 
ºC and the Tg of PLGA was detected between 35-50 ºC. It is preferable that the body 
temperature is not higher in comparison to the Tg for PLGA or Tm for PCL, as it otherwise 
could potentially cause excessive polymer relaxation and likely not allow for long term 
antigen delivery.  
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Figure 9 NMR spectra for (a) High MW PLGA, (b) Med MW PLGA, and (c) Low 
MW PLGA (d) High MW PCL (e) Med MW PCL (f) Low MW PCL. 
PLGA (CDCL3: 7.26ppm) 
0.88 ppm: CH3(CH2)10(CH2)O-O-[(CO)CH(CH3)]x-[O(CO)(CH2)O]y-H 
1.25 ppm: CH3(CH2)10(CH2)O-O-[(CO)CH(CH3)]x-[O(CO)(CH2)O]y-H 
1.55-1.0 ppm: CH3(CH2)10(CH2)O-O-[(CO)CH(CH3)]x-[O(CO)(CH2)O]y-H 
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2.03ppm: CH3(CH2)10(CH2)O-O-[(CO)CH(CH3)]x-[O(CO)(CH2)O]y-H 
4.16ppm: CH3(CH2)10(CH2)O-O-[(CO)CH(CH3)]x-[O(CO)(CH2)O]y-H 
4.73-4.83ppm: CH3(CH2)10(CH2)O-O-[(CO)CH(CH3)]x-[O(CO)(CH2)O]y-H 
5.20ppm: CH3(CH2)10(CH2)O-O-[(CO)CH(CH3)]x-[O(CO)(CH2)O]y-H 
PCL (CDCL3: 7.26ppm) 
0.9ppm: H[(CH2)(CH2)(CH2)(CH2)(CH2)(CO)O]n-O(CH2)(CH2)10CH3 
1.25-1.35ppm: H[(CH2)(CH2)(CH2)(CH2)(CH2)(CO)O]n-O(CH2)(CH2)(CH2)9CH3 
1.38-1.42ppm: H[(CH2)(CH2)(CH2)(CH2)(CH2)(CO)O]n-O(CH2)(CH2)(CH2)9CH3 
1.62-1.71ppm: H[(CH2)(CH2)(CH2)(CH2)(CH2)(CO)O]n-O(CH2)(CH2)(CH2)9CH3 
2.28-2.60ppm: H[(CH2)(CH2)(CH2)(CH2)(CH2)(CO)O]n-O(CH2)(CH2) (CH2)9CH3 
4.04-4.09ppm: H[(CH2)(CH2)(CH2)(CH2)(CH2)(CO)O]n-O(CH2)(CH2) (CH2)9CH3 
The 1H NMR spectra were used to confirm the identity of the synthesized 
polymers and were also used to estimate the molecular weights based on the chemical 
shifts and integration ratios for PCL and PLGA as described by Izunobi, et al. [51] 
(Figure 9). Estimation of MWs were 1700Da for high MW PCL, 900Da for med MW 
PCL and 600Da for low MW PCL. 
27 
3.1.4 Conclusion 
To vary release time of cargo from the polymer, it is likely possible by having 
different molecular weights (or L:G ratios or varying thicknesses of the microbubble 
shell). Therefore, three different molecular weights of both PLGA and PCL was 
synthesized and characterized. Firstly, 1H NMR spectra confirmed the successful 
synthesis of PCL and PLGA and MWs were estimated as 1.7 kDa for High MW PCL, 
0.9 kDa for Med MW PCL and 0.6 kDa for Low MW PCL by NMR peak calculation. 
DSC analysis revealed a Tm value ranging between 45-65 ºC of for PCL and a Tg 
ranging from 20-70 ºC for PLGA. PCL showed a lower and narrower dynamic viscosity 
range (4-16 mPa.s) than PLGA (4-60 mPa.s) when shear stress rates were varied from 
100 to 1000 1/s.  
3.2 SYNTHESIZE ACRYLATE POLYMER FOR MICROBUBBLE 
3.2.1 Introduction 
The initial attempts to synthesize the PCL microbubble indicated there were 
structural defects. Regardless of the concentration of PCL microbubbles, pores with 20-
38 µm diameter were observed from the surface of the PCL microbubbles (Figure 10). 
Such defects were possibly caused by the diffusion of the dissolved chloroform from the 
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PCL microbubble before and possibly during the initial stages of lyophilization. The 
cargo could escape from the microbubble before the expected release date through these 
defects. Thus, using non-cured PCL microbubbles were considered an insufficient 
polymer for forming microbubbles Because of the structural issue of the PCL 
microbubbles, three-dimensional PCL acrylate networks were explored as an alternative. 
The PCL acrylate was also synthesized in-house. Synthesized PCLTA was mixed with 
purchased Mn 14 kDa PCL, since the microbubble, which was fabricated using 
synthesized high MW PCL (around 900 Da MW), was not rigid enough after 
lyophilization. 
Figure 10 Scanning electron microscopy (SEM) imaging depicts pores and defects 
on the surface of PCL. 
PCL acrylate was synthesized from PCL triol which was acrolyated into a PCL 
triacrylate (PCLTA). Cai, et al. described a synthetic pathway that employs potassium 
carbonate (K2CO3) as a proton scavenger instead of trimethylamine (TEA) [52]. TEA 
(a) (b)
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complexes with acryloyl chloride and can produce a colorized compound that can affect 
the photo-crosslinking and cytotoxicity [52]. The relevant features of the PCL acrylate 
synthesis are (i) room temperature synthesis, (ii) adjustable and fast UV curing, and the 
(iii) TEA-related cytotoxicity could be eliminated. 
This section describes the synthesis of PCLTA as an alternative of PCL 
microbubbles. To choose the adequate synthesis, two PCLTA syntheses were performed. 
One used TEA and another used K2CO3. In order to optimize the ratio between PCL and 
PCLTA, varying ratios were made and cured under UV.  We also wanted to determine 
the minimum UV curing time to prevent unnecessary exposure of the cargo which could 
be potentially damaged by the UV.  
3.2.2 Materials and Methods 
3.2.2.1 Materials 
Poly(ɛ-caprolactone) triacrylate (PCLTA) was synthesized using acryloyl 
chloride (Alfa Aesar), K2CO3 (ACROS Organics), poly(caprolactone)triol (PCL triol, 
average MW 300 Da) (ACROS Organics). Dichloromethane (DCM) (ACROS Organics) 
is used for the solvent. 
Synthesized PCLTA and other reagents included poly(ɛ-caprolactone) (PCL, 
average Mn 14 kDa (we purchased this PCL because our previously synthesized PCL 
was insufficient, even after many batches for forming microbubbles and keeping the 
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cargo within)) (Sigma Aldrich), chloroform (Fisher Chemical), ethyl ether (Fisher 
Chemical) and 2-Hydroxy-2-methylpropiophenone relatively more hydrophobic photo 
initiator, in comparison to traditional irgacure) (TCI AMERICA) were used for curing 
the polymer. 
3.2.2.2 PCLTA synthesis 
PCLTA was synthesized with two different methods based on papers. The main 
difference between two methods is the proton scavenger. One of them used TEA and the 
other one used K2CO3. The method using TEA started by loading 2 mM (561 µL) of 
PCL triol to the round bottom flask (Figure 11). 40 µL of toluene was added to dissolve 
PCL triol. The solution was stirred in the 80 ºC oil bath. 4.5 mM (630 µL) of TEA and 
4.5 mM (370 µL) of acryloyl chloride were added dropwise. After 3 hours of reaction, 
the mixture was filtered and purified using hexane in the ice bath. The product was dried 
in the reduced vacuum at 40 ºC for 24 hours, and analyzed by NMR. 
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Figure 11 Synthesis of PCLTA using TEA [53]. © 2003 Elsevier 
The second method used K2CO3. K2CO3, PCL triol, and acryloyl chloride were 
measured in a 3:1:3 molar ratio. 4.1463 g of K2CO3was dried in a 97.5 ºC oven 
overnight. 3.2 mL of PCL triol stock was placed in a round bottom flask and also dried 
under reduced pressure at 50 ºC using a secondary mineral oil container overnight. 2- 
fold volume excess of DCM was added to the PCL triol and continuously stirred at room 
temperature. K2CO3 was then added to the PCL triol. 2.72 mL of acryloyl chloride which 
was mixed with 10-fold volume excess of DCM was added to the mixture of K2CO3 and 
PCL triol, in a dropwise fashion. The reaction was allowed to continue for 24 hrs and the 
mixture was then vacuum-filtered. For purification, the filtered mixture was added drop-
by-drop in 3-fold volume excess of diethyl ether which was in a secondary container 
functioning as an ice bath. After overnight in a vacuum chamber, the purified PCLTA 
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was collected. NMR was used for confirming the acrylate peaks in the final PCLTA 
product. The same method was used to synthesize PCLDA. The synthesis of PCLDA 
and PCLTAs is described in Figure 12. 
Figure 12 Synthesis of PCL acrylates (PCL diacrylate from PCL diol and PCL 
triacrylate from PCL triol) using K2CO3 in DCM at room temperature. 
3.2.2.3 Curing PCL/PCLTA 
PCL (Mn 14 kDa) was dissolved in chloroform at a concentration of 600 mg/mL. 
This PCL solution was mixed with the previously synthesized PCLTA in various volume 
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ratios (PCL:PCLTA=1:0, 1:1, 1:3, 3:1, and 0:1). The photoinitiator was dissolved in 
chloroform at a 5 mg/mL concentration (or 0.5%, assuming the density of water). The 
photoinitiator solution was then added in 1:1 volume ratios with various mixtures of 
PCL/PCLTA. 150 µL of the 1:1 mixture was then added in the caps of 0.5 mL tubes. 
Each of the caps filled with acrylate-terminated and non-acrylate-terminated polymers at 
various ratios were cured under the UV lamp for 20 minutes using an inert atmosphere 
of argon.  
To determine the minimum curing time required for curing PCL (14 kDa 800 
mg/mL):PCLTA:photoinitiator (5 mg/mL) was mixed at a 1:2:1 volume ratio. 150 µL of 
the PCL/PCLTA and photoinitiator mixtures were added within the 0.5 mL tubes, and 
each of the solutions were cured for under the UV lamp for 5, 10, 15 and 20 minutes. 
3.2.3 Results and discussion 
3.2.3.1 PCLTA synthesis 
The NMR results from PCLTA using TEA and PCLDA using K2CO3 did not detect 
acrylate peaks. However, PCLTA using K2CO3 did detect acrylate peaks between 6.40 
and 5.75 ppm (Figure 13).  
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Figure 13 1H NMR spectra for PCLTA. 
PCLTA(CDCL3: 7.26ppm) 
5.73, 5.97ppm: [(CH2)(CH)(CO)O]3[(CH2)(CH2)(CH2)(CH2)(CH2)(CO)O]n(CH2)3-
C(CH2)(CH3) 
6.11ppm: [(CH2)(CH)(CO)O]3[(CH2)(CH2)(CH2)(CH2)(CH2)(CO)O]n(CH2)3-
C(CH2)(CH3) 
4.16ppm: [(CH2)(CH)(CO)O]3[(CH2)(CH2)(CH2)(CH2)(CH2)(CO)O]n(CH2)3-
C(CH2)(CH3) 
1.66ppm: [(CH2)(CH)(CO)O]3[(CH2)(CH2)(CH2)(CH2)(CH2)(CO)O]n(CH2)3-
C(CH2)(CH3) 
35 
1.41ppm: [(CH2)(CH)(CO)O]3[(CH2)(CH2)(CH2)(CH2)(CH2)(CO)O]n(CH2)3-
C(CH2)(CH3) 
1.61ppm: [(CH2)(CH)(CO)O]3[(CH2)(CH2)(CH2)(CH2)(CH2)(CO)O]n(CH2)3-
C(CH2)(CH3) 
2.31ppm: [(CH2)(CH)(CO)O]3[(CH2)(CH2)(CH2)(CH2)(CH2)(CO)O]n(CH2)3-
C(CH2)(CH3) 
4.08ppm: [(CH2)(CH)(CO)O]3[(CH2)(CH2)(CH2)(CH2)(CH2)(CO)O]n(CH2)3-
C(CH2)(CH3) 
1.69ppm: [(CH2)(CH)(CO)O]3[(CH2)(CH2)(CH2)(CH2)(CH2)(CO)O]n(CH2)3-
C(CH2)(CH3) 
0.82ppm: [(CH2)(CH)(CO)O]3[(CH2)(CH2)(CH2)(CH2)(CH2)(CO)O]n(CH2)3-
C(CH2)(CH3) 
3.2.3.2 Curing PCL/PCLTA 
The following assessment within section 3.2.2.2 regarding the curing of 
PCL/PCLTA was qualitative in nature. The polymer mixture, which contained a higher 
PCLTA ratio, had greater rigidity after curing. Therefore, sample 5 (PCL:PCLTA= 0:1; 
control) was the most rigid polymer, which could not be punctured using pipette tips. 
Sample 1 (PCL:PCLTA=1:0) was not cured at all. The color of sample 2, 3, and 4 was 
cloudy but only PCL and only PCLTA polymer were clear after curing (Figure 14). We 
opted to go with the PCL:PCLTA 1:3 because we need to be able to add polymer of a 
36 
higher molecular weight than PCLTA which was only made from PCL-triol that was 300 
Da. 
To cure the all of the polymer, as indicated by the visual presence of uncured 
polymer, within the cap, it required at least 10 minutes. After curing for 5 minutes, only 
the surface of the polymer was cured and it was easily manually broken. At 10 minutes, 
all of the polymer was cured and it was difficult to break using pipette tips. At 15 
minutes, the polymer was breakable using needles but not with pipette tips. Therefore, 
10 minutes was applied for curing every microbubble. 
Figure 14 PCLTA polymer with different ratios after UV curing (1) 
PCL:PCLTA=1:0 (2)PCL:PCLTA= 1:1 (3)PCL:PCLTA= 1:3 (4) PCL:PCLTA= 
3:1(5) PCL:PCLTA= 0:1. 
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3.2.4 Conclusion 
PCL microbubbles showed defects on the surface using the 14 kDa PCL polymer 
which was purchased during the lyophilization process of the formed microbubbles, 
regardless of the concentration used. Therefore, PCL alone in an uncured stated was 
considered to not form microbubbles well, leading us to endeavor curing the 
microbubble.  
This limitation was mitigated by synthesizing the PCLTA polymer via K2CO3, 
acryloyl chloride, and PCL triol. The PCLTA was analyzed by NMR and the result 
indicated acrylate peaks which was also functionally demonstrated with the UV curing 
process itself. The crosslinking between PCLTA monomers occurred under UV light and 
this network was likely sufficiently rigid to form UV-curable microbubbles.  
The PCLTA and PCL solution was mixed with different ratios. Higher PCLTA content 
resulted in more rigid polymers. Optimized ratios of PCL:PCLTA was 1:3, and the 
minimum curing time was 10 minutes. 
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3.3 ENGINEER STABLE MICROBUBBLES THROUGH UV CURE AND 
LYOPHILIZATION 
3.3.1 Introduction 
PCL is considered to be a relatively biocompatible polymer for specific 
applications. Generally, PCL degrades slower than most ester-based polymers used for 
drug delivery systems (i.e., vs PLGA). Due to its hydrophobic properties, PCL has been 
known to facilitate transportation across cellular membranes. PCL also has tunable 
properties which can be modified by altering the chemical structure in its backbone [54]. 
The microbubble topography was assessed by scanning electron microscopy 
(SEM). In this technique, a topographical image is obtained by the electron beam that 
scans the surface of the sample. When conducting SEM, the surface of the sample 
should be conductive or should present a conductive coating (e.g. gold). Also, 
conventional SEM operates in a vacuum and the sample must be previously dried. Thus, 
SEM has limitations when imaging biological samples (for example, plasma membrane 
interactions, cells, tissues), which can lose the native structure or surface properties) 
[55]. At the scale and resolution, we need to image the microbubble, however, SEM is of 
high utility. 
In this work, PCL microbubbles were formed in DI water using various 
concentrations. Images of the surface of PCL microbubbles were taken by SEM after 
lyophilization, and the structural limitations were subsequently discussed.  
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PCL/PCLTA microbubbles were also formed in water. Through SEM images after UV 
curing and lyophilization, it was identified that UV curing of the PCL/PCLTA 
microbubble resolved the structural problems of the PCL microbubbles which were 
shown in Figure 10. The optimization of PCLTA cross-linking by UV curing enabled us 
to seal the cargo inside the PCLTA microbubble, which would then enable us to 
modulate the kinetics of the cargo release using the shell of the microbubble. The freeze-
drying processes are expected to aid the removal of water which would otherwise affect 
the stability of the cargo within. Of note, initially we synthesized PCL which was 
excessively low in MW, which made it difficult to form microbubbles from so we began 
using commercially purchased 14 kDa PCL. Below we will be discussing the use of 14 
kDa and 80 kDa PCL to enable us to compare MW differences. Unfortunately, in the end 
we were not able to mix PCLTA with 80 kDa PCL which is required to cure the polymer 
because they phase separated, thus we ended up not being able to continue using 80 kDa 
PCL for formation of the microbubbles. To compare differing molecular weights of 
polymer we ended up using 14 kDa PCL and 45 kDa PCL. 
3.3.2 Materials and Methods 
3.3.2.1 Materials 
Chloroform (Fisher Chemical) and poly(ɛ-caprolactone) (PCL, average Mn 80 
kDa) (Sigma Aldrich) was purchased to form PCL microbubbles.  Synthesized PCLTA, 
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Poly(caprolactone) (PCL, average Mn 14 kDa) (Sigma Aldrich), and 2-Hydroxy-2-
methylpropiophenone (photoinitiator) (TCI AMERICA) were used for PCL/PCLTA 
microbubbles. Legato 100 Syringe Pump (KD Scientific) was used for the microbubble 
injection. 1 dram of borosilicate glass vial (VWR) was used for microbubble container. 
3.3.2.2 PCL microbubble (80 kDa) 
14 kDa and 80 kDa PCL is used to 80 kDa PCL was dissolved in chloroform as 
various concentration; 100 mg/mL, 400 mg/mL, 600 mg/mL, 800 mg/mL, and 1000 
mg/mL (not accounting for polymer volume itself; thus, these concentrations would be 
90.9, 286, 375, 444, and 500 mg/mL, respectively, when accounting for polymer 
volume). Each polymer was aspirated from a primary container into a 250 mL glass 
syringe using a 21 G needle. A nickel titanium alloy (Nitinol) tube was used for injecting 
the organic solvent phase containing solvated polymer into the water phase. The Luer 
lock and the Nitinol tubing were glued together using epoxy glue and was allowed to dry 
overnight. DI water was filled in the borosilicate glass vial and polymer was injected 
into this vial through the Nitinol tube which was connected to a syringe pump. The 
polymer injection rate of the syringe was controlled by the syringe pump at a rate of 0.5 
µL/sec. The formed bubble was frozen in liquid nitrogen for 20 minutes and lyophilized 
overnight. The microbubble surface was then analyzed by SEM. The inner portions of 
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the microbubble using the highest concentration (1000 mg/mL) was imaged by breaking 
the microbubbles open with forceps. 
3.3.2.3 PCL/PCLTA (14 kDa) microbubbles 
14 kDa PCL was dissolved in chloroform and the concentration used was 800 
mg/mL. This PCL was mixed with PCLTA and 0.005 g/mL photoinitiator as 1:3:2 
volume ratio. The polymer was loaded and injected into the glass vial in the same way as 
the aforementioned PCL microbubble (3.3.1.2). The formed microbubble was cured 
under UV light for 10 minutes. After it was confirmed that the microbubble was cured, it 
was frozen in liquid nitrogen for 20 minutes and lyophilized overnight. The surface of 
PCL/PCLTA microbubbles were also analyzed by SEM. 
3.3.3 Results and discussion 
3.3.3.1 PCL microbubble (80 kDa) 
PCL concentrations were varied from 100 mg/mL to 1000 mg/mL From 100 
mg/mL to 400 mg/mL microbubbles were hollow, similar to (a) and (b) in Figure 15. 
Therefore, they easily collapsed when they were picked up and removed from the 
solution. From 600 mg/mL to 1000 mg/mL, microbubbles were rigid enough to take out 
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Figure 15 SEM images of 80 kDa PCL microbubbles surface at (a) 100 mg/mL, (b) 
400 mg/mL, (c) 600 mg/mL, (d) 800 mg/mL, and (e) 1000 mg/mL and inside of PCL 
microbubbles at (f) 400 mg/mL and (g) 1000 mg/mL. 
using forceps. However, these hard bubbles were cracked easily during the 
lyophilization process. From the image of the inside of the microbubbles, denser inner 
(a) (b)
(c) (d)
(e) (f)
(g)
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surfaces were observed using 1000 mg/mL (500 mg/mL accounting for polymer volume) 
microbubbles, while 100 mg/mL microbubble showed an inner surface with many pores.  
3.3.3.2 PCL/PCLTA microbubbles 
The main difference was shape when PCL and PCL/PCLTA microbubbles were 
formed in the glass vial. The PCL microbubble was spherical in shape from when it was 
formed to when it even sank to the bottom, but PCL/PCLTA microbubble became a 
hemisphere when it touched the bottom of the glass vial (Figure 16). 
Figure 16 Shape of microbubbles formed in the water:  
(a) 80 kDa PCL microbubble after lyophilization (UV curing was previously done 
on this and did not cure as expected so was not done so in this particular 
experiment) and (b) 14 kDa PCL/PCLTA microbubble after UV curing and 
lyophilization. 
(a) (b)
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Also, when the microbubble became a hemisphere shape, as shown in Figure 17 
the diameter of microbubble increased from 0.69 mm to 1.90 mm.  Even though the 
shape was a hemisphere, the SEM image showed that the defects of the microbubble 
surface were rectified. 
Figure 17 SEM images of PCL/PCLTA microbubbles from the (a) front, (b) 
bottom, (c) and side views. 
(a
)
(b
)
(c
)
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3.3.4 Conclusion 
The structure of PCL and PCL/PCLTA microbubbles were analyzed by SEM after 
formation, freezing, and lyophilization. PCL microbubbles showed different rigidity 
depending on the concentrations. For example, 100 and 400 mg/mL PCL microbubbles 
were unable to maintain their spherical shapes due to its hollow and porous structure. 
600, 800, and 1000 mg/mL microbubbles maintained their spherical shapes, but they 
cracked during the lyophilization process. Regardless of the concentrations, 80 kDa PCL 
microbubbles at every concentration indicated surface defects. 
PCL (14 kDa)/PCLTA microbubbles were formed as an alternative to PCL (80 
kDa) microbubbles. Because PCL/PCLTA microbubbles are less rigid than PCL 
microbubbles, the surface that touched the glass vial became flat and it was cured in the 
hemisphere shape using UV light. However, we observed that there was no surface 
defect on the PCL/PCLTA microbubble surface.  
Future work from this point will involve preserving the spherical shape of 
PCL/PCLTA microbubbles using various solutions. 
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3.4 ENGINEERING THE MICROBUBBLE TO BE STATIONARY FOR 
MAINTAINING SPHERICAL SHAPE DURING THE CURING PROCESS 
AND THE INJECTION OF THE CARGO 
3.4.1 Introduction 
In the previous section, we observed PCL/PCLTA sank in the glass vial, which 
was filled with water, and the microbubble formed a hemispherical shape. This 
hemispherical shape is not proper for controlling drug release because the distance from 
the cargo to the microbubble surface is not even as it is for a spherical shape. The 
hemisphere would make it unnecessarily difficult to control the release profile. 
Furthermore, it would likely be easier to have a spherical microbubble flow through the 
highest gauge needle possible, in comparison to the hemispherical shape. To maintain 
the spherical shape of microbubbles, the solution requires higher viscosity. 
A direct injection of cargo into the microbubble requires a matrix that could 
provide enough mechanical support to hold the microbubble firmly during the injection 
in order to avoid the microbubble from touching the wall and lying flat. Moreover, the 
microbubble matrix should be transparent to UV light in order to allow for the PCLTA 
to cure. The microbubble matrix should avoid having the PCLTA diffuse through it to 
maintain the microbubble shape.  
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Several substances were tested as a microbubble matrix, such as polyethylene 
glycol (PEG) hydrogel, hydroxyethyl methacrylate (HEMA) hydrogels, a trehalose 
solution, agarose, and carboxymethyl cellulose (CMC; 5% and 10% solutions). 
3.4.2 Materials and Methods 
3.4.2.1 Materials 
2,2-dimethoxy-2-phenylacetophenone (DMPA) (Acros Organics), ethylene 
glycol (Fisher Chemical), 2-hydroxyethyl methacrylate 97% (HEMA) (ACROS 
Organic), triethylene glycol dimethacrylate (TEGDMA) (TCI America) were used for 
HEMA gel. 
carboxymethyl cellulose (CMC, sodium salt, low viscosity) (Millipore Sigma), agarose 
(Fisher BioReagents), trehalose (Acros Organics) were also purchased for preparing the 
solvent. 
Synthesized PCLTA, Poly(ε-caprolactone) (PCL, average Mn 14 kDa) (Sigma 
Aldrich), and 2-hydroxy-2-methylpropiophenone (photoinitiator) (TCI AMERICA) were 
used for PCL/PCLTA microbubbles. A Legato 100 Syringe Pump (KD Scientific) was 
used for the microbubble injection. 1 dram of borosilicate glass vial (VWR) was filled 
with the various solutions as a primary microbubble container. 
48 
3.4.2.2 HEMA hydrogel 
Three different HEMA hydrogels were synthesized. Before initiating the 
synthesis, HEMA and TEGDMA were passed through an inhibitor remover column and 
the solutions were then collected in glass vials. 5 mg of DMPA was measured, 10 µL of 
TEGDMA and 490 µL of HEMA were added together. 180 µL of ethylene glycol was 
added as a solvent and mixed. 100 µL, 200 µL, and 300 µL of water was added to render 
varying rigidities. The polymer was cured using UV for 10 minutes. The PCL/PCLTA 
microbubbles were injected through a 25 G needle. 
3.4.2.3 HEMA hydrogel + 1.5% (final) CMC 
CMC was dissolved in DI water as a 3% (w/v) solution.  The same formulation 
of HEMA gel and 3% CMC solution was mixed in a 1:1 volume ratio. The mixture of 
HEMA and CMC was then cured using UV for 15 minutes. The PCL/PCLTA 
microbubbles were injected through a syringe pump at a rate of 0.5 µL/sec. 
3.4.2.4 Trehalose 
A 60% (w/v) trehalose solution was prepared by dissolving 6 mg of trehalose in 
10 mL of DI water. 60% was used because 68% is the solubility limit and we wanted to 
make as viscous of a solution as possible without being concerned with the trehalose 
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being completely solvated. The PCL/PCLTA microbubbles were injected at a syringe 
pump rate of 0.5 µL/sec. 
3.4.2.5 5% and 10% CMC 
5% and 10% (w/v) CMC solutions were prepared by dissolving CMC in DI 
water. PCL/PCLTA microbubble was injected through syringe pump as 0.5 µL/sec rate. 
3.4.3 Results and discussion 
A microbubble could not be formed in a PEG hydrogel nor a HEMA hydrogel 
matrix (Figure 18a). These hydrogels were too dense, so the polymer was formed along 
the needle injection path, as the polymer solution followed the path of least resistance. 
The injected polymer was not able to be visualized in the HEMA hydrogel using 100 µL 
and 200 µL of water (Figure 18b). When HEMA hydrogel contained more than 400 µL 
of water, it turned even cloudier making the already not visible polymer even more 
difficult to see. We felt this would complicate the project so we opted to not use HEMA 
for our microbubble project. 
There was another trial after injection to the hydrogels. The hydrogel was cured 
from the bottom of the glass vial. The glass vial was taken out from the UV station 
during the curing but before the gel was fully cured, and a microbubble was injected 
through the HEMA precursors onto the lower cured portion of HEMA. The curing likely 
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began from the bottom up, even though the UV light came from the top because there 
was less oxygen at the bottom, as this was not done under inert gas due to issues with the 
liquid spraying under the flow of the gas and difficulties with creating a gas chamber 
that would flow slowly enough into the vial. However, the microbubble surface, which 
came into contact with the HEMA hydrogel became flat, similar to previous 
observations when the microbubble touched the glass vial (Figure 18c). To increase the 
viscosity of the HEMA 5% CMC was mixed prior to UV curing. However, it was cloudy 
after UV curing (and became increasingly so with the addition of water), so the 
microbubble itself post-injection could not be visualized (Figure 18d). 
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Figure 18 PCL/PCLTA polymer was injected in (a) PEG hydrogel and the polymer 
followed the path of the needle (b) a HEMA hydrogel with 13% (left), 23% 
(middle), and 31% (right) v/v water content; in (c)half-cured HEMA hydrogel (UV 
light directed from the top; the bottom portion likely cured first because it had less 
oxygen near the bottom of the vial; top contains uncured HEMA precursors) (d) 
HEMA+1.5% (final) CMC and subsequently cured (e) 60% (w/v) trehalose (f) 
agarose gel on the bottom with pure water atop (g) 10% CMC.  
Even though the trehalose solution seemed to have had a higher viscosity than 
water, as literature indicates the microbubbles sank in the 60% (w/v) trehalose solution 
as fast as microbubbles in the DI water in the borosilicate glass vial. The microbubbles 
(f)
(a) (c)
(d)
(b)
(e) (g
)
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in trehalose solution also became hemispherical when the microbubbles touched the 
glass vial, similar to when the microbubbles were formed in the DI water. (Figure 18e). 
Microbubbles on the agarose gel were closer to a sphere than other solution such 
as the HEMA and PEG hydrogels or the trehalose solution, but the surface of 
microbubbles which touched the agarose gel was more flat than other parts of the surface 
(Figure 18f). 
Figure 19. PCL/PCLTA microbubbles reached the bottom of the glass vial in a 5% 
CMC solution (a) which caused a flattened bottom on the microbubble and (b) 
the microbubble did not reach the bottom of the glass vial when using a 10% CMC 
solution. 
Among the various solvents tested, the CMC solutions had the highest viscosity. 
In a 5% CMC solution, the microbubbles sank slowly. After UV curing the microbubble 
eventually did reach the bottom of the glass vial, so it resulted in a slightly flattened 
bottom shape (Figure 19a). However, the microbubble was completely suspended in 
(a) (b)
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10% CMC solution. Even after UV curing the microbubble was suspended in the same 
position which it was formed and also maintained the spherical shape (Figure 18g and 
19b). 
3.4.4 Conclusion 
As shown in section 3.3, PCL/PCLTA microbubbles are less rigid than PCL 
microbubbles. Therefore, PCL/PCLTA microbubbles changed the shape to be 
hemispherical when the microbubbles touched the glass vial. To avoid this shape 
change, various solutions were explored. PEG hydrogels and HEMA hydrogels were 
synthesized using different water contents. The half-cured HEMA hydrogel and the 
mixture of HEMA and 1.5% CMC were also used. Furthermore, a trehalose solution, an 
agarose gel, and 5% and 10% CMC solutions were prepared. 
Microbubbles could not be formed into a spherical shape using PEG and HEMA 
hydrogels due to the hydrogel’s density. In the context of the half-cured HEMA 
hydrogel, the microbubbles’ surface, which touched the cured HEMA hydrogel, became 
flat. When the HEMA hydrogel was mixed with 5% CMC the gel changed to cloudy 
after curing, so microbubble could not be visualized. Microbubbles sank immediately in 
trehalose solution like that in water. 5% CMC was viscous but not enough to suspend 
microbubbles. Therefore, the microbubble sank slowly and touch the glass vial during 
the UV curing. However, the microbubble was suspended in 10% CMC. The only 
suitable solution for forming spherical microbubbles that allow for enough stability to 
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inject cargo was the 10% CMC. Even after curing and lyophilization, the shape was 
completely sphere. 
Future work will entail ensuring the cargo within the microbubble remains 
stationary within the spherical microbubble to maximize the release kinetics for a given 
diameter of microbubble. The next section describes how to increase the viscosity of the 
cargo to cause the cargo bubble within the microbubble to not escape upwards into the 
outer 10% CMC solution. 
3.5 ENGINEERING THE CARGO TO BE STATIONARY WITHIN THE 
POLYMERIC MICROBUBBLE TO MAXIMIZE THE RELEASE TIME 
3.5.1 Introduction 
Single- or double- emulsion techniques are the conventional methods for cargo 
encapsulation within PCL NPs and MPs [56, 57]. This size distribution affects to the 
kinetics of the drug release [58, 59], and it is common to observe sustained releases 
instead of bolus release from the NP/MP using emulsion methods because cargo is 
scattered throughout the microparticle whether it is homogeneously distributed 
(generally for hydrophobic cargo; single-emulsion) and distributed throughout in smaller 
aqueous pockets. Because of the cargo being distributed throughout, there is continual 
release generally for the duration that there is particle mass remaining. There has been 
reports, however, of catastrophic breakdown of ester-based polymers which degrade via 
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bulk degradation at later time points which could potentially serve as a secondary burst 
[25].  
In this section, the encapsulation of cargo within the microbubble is 
accomplished by direct injection using needles. After direct injection, UV curing and 
freeze-drying processes were performed to stabilize the microbubble and avoid cargo 
leakage.  
In order to study the kinetics of the drug release from the PCL/PCLTA 
microbubbles, a BSA conjugated to CF680 dye (BSA-CF680) was used as a model 
antigen which would be useful for in vivo imaging purposes due to the 
excitation/emission being in the near infrared region. We discovered later this excitation 
and emission could not be used with our confocal microscopy available to us at TAMU, 
thus we ended up using a BSA model antigen conjugated to a CF dye which is excited at 
488 nm. Doxorubicin and acriflavine were used as fluorescence indicators for confocal 
microscopy purposes. 
Until the end of UV curing, it is crucial to ensure that the cargo remains inside 
the microbubble. In this section, we ensured the cargo would remain stationary within 
the microbubbles using 3% and 5% CMC, which increased the viscosity of the cargo 
solution. Note that there is 10% CMC that the microbubble is injected into and then a 
3% and 5% CMC solution of cargo is being injected within the microbubble for the 
internal cargo bubble to stay stationary. 
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3.5.2 Materials and Methods 
3.5.2.1 Materials 
Bovine serum albumin (BSA) (Fisher BioReagents) was conjugated with CF680, 
maleimide(Sigma Aldrich). Sephadex G-25 (Sigma Aldrich), anhydrous 
dimethylsulfoxide (DMSO) (Alfa Aesar), and Tris-(2-carboxyethyl)phosphine (TCEP) 
were other materials used for the BSA-CF680 conjugation reaction and purification 
steps. 
This BSA-CF680, acriflavine (Chem-Impex International), and doxorubicin 
hydrochloride (Fisher BioReagents) were used for cargo. Carboxymethyl cellulose 
(CMC; sodium salt, low viscosity) (Millipore Sigma) was used for increasing viscosity 
of cargos. 
Synthesized PCLTA, poly(ε-caprolactone) (PCL, average Mn 14 kDa) (Sigma 
Aldrich), and 2-hydroxy-2-methylpropiophenone (photoinitiator) (TCI AMERICA) were 
used for PCL/PCLTA microbubbles. A 0.5 dram borosilicate glass vial (VWR) was used 
for the primary microbubble container. 
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3.5.2.2 BSA-CF680 conjugation 
12 mM of protein was prepared by dissolving 0.006 mmol of BSA in 0.5 mL 
PBS. A 10-fold molar excess of TCEP was added to reduce the disulfide bonds within 
the BSA to thiol groups. BSA with TCEP was stirred for 30 minutes under argon gas. 
0.4 mL of anhydrous DMSO was added to 1µmole of CF680 maleimide, thus a 2.5 mM 
dye solution was prepared. The vial was vortexed to be fully dissolved and briefly 
centrifuged to collect as much of the solution as possible. 
The 0.036 mL of dye stock was added to the stirring BSA solution in a 
dye/protein molar ratio of 15. The mixture was stirred at room temperature for 2 hours. 
The Sephadex G-25 column was equilibrated in PBS buffer for separating the 
labeled BSA from the free dye. The Reaction Solution was loaded onto the column. The 
column was eluted with 1× PBS buffer. After excluding the first band, labeled BSA was 
collected. 
3.5.2.3 Cargo injection with and without CMC 
1% (w/v) acriflavine solution was prepared by dissolving 5 mg acriflavine in 0.5 
mL PBS. 1% (w/v) doxorubicin was also prepared in the same way. BSA-CF680 
conjugates, 1% (w/v) acriflavine and 1% (w/v) doxorubicin was loaded into the 1 mL 
syringe. The glass vial is filled with 10% CMC solution, and PCL/PCLTA microbubble 
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using 14 kDa 1000 mg/mL PCL was formed. The syringe pump rate was 0.5 µL/sec for 
10 seconds, and three different cargo was injected into three different microbubbles 
using 34 G blunt tip needles.  
To prepare cargo with CMC 9 mg, 15 mg of CMC is weighed in each microtube. 
By adding 0.3 mL of 1% (w/v) acriflavine solution to each CMC microtube, cargo with 
3% and 5% (w/v) CMC were prepared. 1% (w/v) Doxorubicin and stock of BSA-CF680 
in 3% and 5% CMC also prepared in same way. Microbubbles were formed in 10% 
CMC vial using same syringe pump rate. Six different cargo solutions were loaded into 
the 1 mL syringe and injected into the six different microbubbles using 34 G blunt tip 
needles. 
3.5.3 Results and discussion 
3.5.3.1 BSA-CF680 conjugation 
After conjugation of CF680 and BSA, each concentration was calculated using 
the Beer-Lambert Law. 
A = εcl 
A = the absorbance of dye or BSA 
ε = the molar absorption coefficient or extinction coefficient (L mol-1 cm-1 or M-1cm-1). 
c = the concentration of the dye or BSA (mol L-1) 
l = the wavelength path length (cm). 
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For CF680 dye, the absorbance, the molar absorption or extinction coefficient, 
and the wavelength path length were 1.437, 210,000(L mol-1 cm-1), and 0.294cm, 
respectively.  
1.437 = 210,000 (L mol-1 cm-1) x c x 0.294cm.  
Therefore, the concentration of dye was 0.0232 mM.   
For BSA, the absorbance, the molar absorption coefficient, and the wavelength 
path length were 0.149, 43,824(L mol-1 cm-1), and 0.294cm, respectively. 
0.149 = 43,824 (L mol-1 cm-1) x c x 0.294cm. 
Therefore, the concentration of BSA was 0.0115 mM. The concentration of 
BSA-CF680 conjugates was calculated using ABSA(corrected) = A280 – (Amax * CF). 
A280 = absorbance readings of the conjugate at 280 nm 
Amax = the absorption at 681 nm 
CF = the absorbance correction factor 
CF was 0.09 for CF680, therefore,  
ABSA(corrected) = 1.437 - (0.149 x 0.9) = 0.0193. 
0.0193 = 43,824 (L mol-1 cm-1) x c x 0.29422cm, so the corrected BSA concentration 
0.0015 mM. The ratio of CF680 dye to BSA is 15.5 to 1.  
Based on this calculation, the calibration curve using half dilution series of BSA-
CF680 conjugates was prepared (Figure 20). There is a total of 17 disulfide bonds in 
BSA, thus after the reduction process there is a total of 34 thiol groups which could react 
with the maleimide. Because we had a ratio of 15.5:1 dye:BSA then we know that there 
the dye conjugation process was at 45.6% of the maximum saturation.  
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Figure 20. Calibration curve of BSA-CF680 conjugates (Cytation 5 was set to a gain 
of 100 and a bandwidth of 9 nm). 
3.5.3.2 Cargo with CMC 
Without CMC, the cargo inevitably escaped immediately upon injection within 
the microbubble, as shown in Figure 21. Through the confocal microscopy, the 
fluorescence dye was observed only from the surface of the microbubble but not inside 
the microbubble because the cargo escaped (Figure 22a). However, the cargo remained 
within the microbubble when injected with the CMC solution. However, an amount of 
the drug was also presumed to escape out of the conduit which the cargo tube had made 
while the cargo tube was pulled out of the shell of the microbubble. The dye 
preferentially would partition into the organic phase, as opposed to the aqueous phase 
which is why the outer perimeter fluoresces in the confocal microscopy images.  
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Figure 21. Cargos without CMC (a) 1% (w/v) doxorubicin (b)BSA-CF680. 
Figure 22. Confocal images after UV curing and lyophilization using (a) 1% (w/v) 
acriflavine without CMC and (b) 1% (w/v) acriflavine with 3% CMC.  
(a) (b)
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Figure 23. Inner cargo bubbles injected with 3% CMC within the microbubbles 
using (a) 1% (w/v) acriflavine (b) 1%(w/v) doxorubicin (c) BSA-CF680 (d) 1% 
(w/v) acriflavine after UV curing. 
When cargo was injected with 3% CMC, they formed the expected inner bubble 
within the microbubble. However, the cargo bubble kept rising to the top of the 
microbubble through the microbubble’s shell as shown in Figure 22b and Figure 23. 
Therefore, if there is a long-time interval between when the cargo is injected and when 
the UV curing takes place, the cargo may escape from the microbubble by migrating 
upwards. When the microbubble was cured immediately after the inner cargo bubble was 
injected using 3% CMC, the inner cargo bubble would migrate to the top of the 
microbubble within 1 minute and remain there (even throughout the remaining UV 
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curing duration and lyophilization. Figure 23(d) shows 1% (w/v) acriflavine with 3% 
CMC after UV curing. 
Figure 24. Cargo with 5% CMC using (a) 1% (w/v) acriflavine and (b) 1% (w/v) 
doxorubicin. 
With 5% CMC, the inner cargo bubbles were stationary within the microbubbles. 
Because of the viscosity of the inner cargo bubble, the cargo did not rise and stayed in 
the middle of the microbubble even during the UV curing process (which the 3% CMC 
was not able to do) and lyophilization. Figure 24 and confocal image of Figure 25 
demonstrate that the cargo using 5% CMC stayed stationary in the middle of the 
microbubbles. 
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Figure 25. Confocal image of 1% acriflavine with 5% CMC. 
3.5.4 Conclusion 
As the cargo, 1% (w/v) acriflavine, 1% (w/v) doxorubicin, and BSA-CF680 
conjugate formulations were prepared and injected into the 14 kDa PCL/PCLTA 
microbubble. Again, at this stage we were not using the 80 kDa PCL because it could 
not be mixed with the PCLTA which is required for curing purposes. These drug 
formulations without CMC escaped as soon as they were injected. Cargo with 3% CMC 
was capable of creating an inner cargo bubble inside of the microbubble, but the inner 
cargo bubble would migrate upwards and remain at the top of the microbubble within 1 
minute. Even though UV curing was started as soon as they were injected, the cargo 
stayed on the top of the microbubble.  
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To ensure the inner cargo bubble remained stationary, we found that a 5% CMC 
concentration was sufficient to keep the inner cargo bubble from migrating upwards 
even throughout the UV curing process (note that cargo can still escape during the initial 
phase of the curing process) as was demonstrated with the confocal microscopy images 
post-lyophilization.  
3.6 QUANTIFY THE DIAMETERS OF THE MICROBUBBLE BY VARYING 
SYRINGE PUMP RATE AND COMPARING DIAMETERS PRE- AND 
POST-LYOPHILIZATION 
3.6.1 Introduction 
It is crucial to control the diameter of the microbubbles in order to control the 
drug release and the injectability through various desired gauges of needles. The 
repeatability of formation of the same diameter of microbubbles and injecting the same 
amount of drug are also important to maintain similar shell thicknesses. Varying 
diameters will affect the uniformity of drug release. The diameters of the microbubbles 
were varied by controlling the syringe pump rate and measured by taking photographs 
and using an electronic micrometer for the calibration of the image itself. The correlation 
between the syringe pump rates and the particle diameters gives us the ability to control 
the end microbubble diameter. 
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In addition, the actual volumes of microbubble using confocal microscopy were 
compared to the theoretical volumes based on the syringe pump rate and the duration of 
injection.  
3.6.2 Materials and Methods 
3.6.2.1 Materials 
Synthesized PCLTA, poly(ε-caprolactone) (PCL, average Mn 14 kDa) (Sigma 
Aldrich), and 2-hydroxy-2-methylpropiophenone (photoinitiator) (TCI AMERICA) were 
used for PCL/PCLTA microbubbles. The glass syringe pump barrel and the tube was 
connected through luer locks. A P-662 female luer (Idex) is for the microbubble 
injection and one Hub Assembled with 12" of Tubing (30 gauge) (Hamilton) is for the 
drug injection. A Legato 100 Syringe Pump (KD Scientific) was used for controlling the 
microbubble injection rate. The micromotor (CONEX-AG-LS25-27P), Piezo Motor 
Linear Stage, was purchased from Newport. A 0.5 dram borosilicate glass vial (VWR) 
was used for the primary microbubble container. 
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3.6.2.2 Controlling the diameter of the microbubble by controlling the syringe 
pump rate 
Figure 26. Microbubble diameter comparisons dictated by the syringe pump rate. 
14 kDa PCL was dissolved in chloroform and the concentration was 800 mg/mL. 
This PCL was mixed with PCLTA as 1:3 volume ratio. 1 µL of the photoinitiator stock 
was added. The polymer was loaded within the glass barrel which was controlled by the 
syringe pump and the tube for the microbubble injection (polymer phase) was connected 
from the glass barrel to the micromotor. The glass vial was filled with 10% (w/v) CMC, 
and the tube was inserted near the bottom of the vial (but not so low that the injected 
polymer microbubble would contact the bottom of the glass vial). Using Labview® the 
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micromotor moved backwards (at the constant and manufacturer’s set rate; the rate 
cannot be controlled by users) while the syringe pump was also extruding polymer. The 
syringe pump rate was controlled from 0.0005 to 1 µL/sec. A photo was taken of the vial 
(Figure 26), and the microbubble diameters were quantified via ImageJ® with the 
calibrated object in the image using the electronic micrometer. 
Confocal microscopy is an optical microscopy technique with an enhanced 
resolution and contrast when compared to a regular micrograph. The main feature is 
imaging confocal planes through a spatial pinhole, which allows the selective 
observation of light from a specific plane and excluding the light from other planes. 
Therefore, the collection of z-stack confocal planes provide a three-dimensional image 
of the sample 69. 
3.6.2.3 Diameter of the microbubble pre- and post-lyophilization 
The precursor of the microbubbles was prepared in a similar manner as was 
described in section 3.6.2.2. The polymer was loaded within the glass barrel which was 
controlled by the syringe pump. The glass vial was filled with 10% (w/v) CMC, and the 
microbubble was injected using a syringe pump at a rate of 0.5 µL/sec. After the 
microbubbles were formed, they were cured by UV for 10 minutes.  
Photos of the microbubbles within the glass vials were taken and the 
microbubble diameters were quantified via ImageJ® with a calibrated object in the photo 
using the electronic micrometer. After lyophilization the diameters of the microbubbles 
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were quantified using the electronic micrometer as well. The reason it is not possible to 
measure the diameters of the pre-cured microbubbles with the micrometer as they are in 
liquid form at that stage. 
3.6.2.4 Diameter of the microbubbles pre- and post-cargo injection 
The precursor of microbubbles was prepared similarly to the microbubbles in 
section 3.6.2.2.  The polymer was loaded within the syringe pump’s glass barrel. The 
borosilicate vial was filled with 10% (w/v) CMC, and the syringe pump was controlled. 
The syringe pump rate was controlled from 0.0005 to 1 µL/sec. After the microbubbles 
were formed, the 1% acriflavine using 5% CMC was injected into the microbubble using 
a 34 G needle. Before and after cargo injection, photos were taken of the microbubbles 
in the glass vial and the microbubble diameters were measured by ImageJ® using a 
calibrated object within the image as measured by the electronic micrometer. 
3.6.3 Results and discussion 
3.6.3.1 Controlling diameter of the microbubbles dictated by the syringe pump rate 
As can be seen from Figure 27, the microbubble size increased from 325±20 µm 
to 799±71 µm when the syringe pump rate increased from 0.005 µL/sec to 1 µL/sec 
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while the micromotor was driven backwards at the constant manufacturer rate. There 
was an increase between 0.005 µL/sec and 0.01 µL/sec from 325 µm to 547 µm. 
Interestingly, the microbubble diameter is not reliable when the syringe pump rate is 
below than 0.005 µL/sec. The inaccuracy at this stage is likely due to the lower limit of 
the syringe pump rate which is 0.0003 µL/sec. It increased from 325±20 µm to 551±23 
µm when the syringe pump rate decreased from 0.005 µL/sec to 0.001 µL/sec in two 
separate experiment. 
Figure 27. Microbubble diameters dictated by the syringe pump rate while the 
micromotors were driven backwards in space. The backwards motion causes 
microbubbles to separate. 
When the microbubble was formed with 0.1 µL/sec rate for 5sec, the volume 
should be 0.5 µL. However, the actual volume was less than that, 0.473454 µL (r= 
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0.4835 mm). Because the syringe pump operation is performed manually, there was 
5.4% of error between the theoretical and actual volumes.  
Figure 28 Confocal images of BSA-CF488 in the microbubble from the middle to 
the bottom of the microbubble (from (a) to (d)). The distance between each slice is 
10 µm. Note that there is drug around the periphery which is due to the escape of 
the drug through the temporary conduit made as the tube used for the cargo 
injection is removed from the liquid shell of the microbubble. (The confocal video 
file was submitted as supplemental file) 
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A confocal microscopy is a characterization technique that helped assess the 
microbubble fabrication and cargo distribution throughout the microbubble (Figure 28). 
3.6.3.2 Diameter of the microbubbles pre- and post-lyophilization 
Figure 29 Microbubbles size comparison before and after lyophilization. 
In both case, without drugs and with drugs, the microbubble was decreased post-
lyophilization by 25±2.5%and 31±3.2%, respectively (Figure 29). This is likely because 
the aqueous phase containing the cargo and chloroform of microbubbles were 
evaporated to the extent possible during the lyophilization. We suspect that the center is 
not as dry as it could be and studies investigating the inner water content will be 
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accomplished in the future as well as endeavoring to vent the inner cargo during the 
lyophilization process, followed by a localized annealing process.  
The diameter of the microbubbles was analyzed pre- and post-lyophilization 
using a Student’s t-test, and the quantified p-values were 0.0014 and 0.0009 for 
microbubbles without drugs and with drugs, respectively. Both values were less than 
0.05, so there were significant diameter differences pre- and post-lyophilization. 
3.6.3.3 Size of the microbubble before and after cargo injection. 
Figure 30. Microbubble diameter comparison before and after cargo injection. 
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When the diameter of the microbubbles before cargo injection was normalized to 
1±0.064, the post-injection diameter was calculated to be 1.084±0.069 was gotten for the 
microbubble size after cargo injection (Figure 30). The volume increased 8.4%, but the 
size difference is not significant because the p-value was 0.199.  
3.6.4 Conclusion 
In this section, we were able to control the microbubble diameter using the 
syringe pump rate. The reliable range was from 0.005 to 1 µL/sec, and the microbubble 
diameters increased from 325±20 µm to 799±71 µm. The microbubble size before 
lyophilization was also compared to after lyophilization. For both microbubbles with and 
without drugs, the microbubble diameter decreased after lyophilization, and both p-
values were less than 0.05. This demonstrates that the bubble diameters decrease 
significantly due to the solvent (water/organic solvent) evaporation. Even though the 
microbubble diameter increased because of the injected drug volume, it was not a 
significant increase (p-value: 0.199) but appeared to be trending towards significance. 
These results enable us to know how to control the system for a given microbubble 
diameter. However, the automation system is required for the repeatability of 
microbubble formation which is an ongoing endeavor within the Pharmacoengineering 
Laboratory (Dr. Corey Bishop’s Laboratory). The next chapter describes how to quantify 
the angle of the micromotors for enabling the polymer injection tube and the cargo tube 
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to meet at the same location within the borosilicate vial. These tubes can be controlled 
by micromotors (translation of the tubes) and a goniometer (angling the tube). 
3.7 QUANTIFYING THE ANGLE OF THE MICROMOTORS FOR 
INJECTING CARGO INTO THE CENTER OF THE MICROBUBBLES 
3.7.1 Introduction 
After setting the initial conditions for the microbubble formation, it is important 
to secure the repeatability. Since the microbubble fabrication was performed manually, 
the bubble size and injected drug amount are slightly different every time. Also, the 
position, which microbubbles are capable of forming, is variable in the outer 10% CMC 
solution that the microbubbles are injected into when the system is not automated.  
In order to form the microbubble, inject cargo, UV cure, freeze and lyophilize in an 
automated fashion, this entire system needs to be self-contained in a container which can 
withstand lyophilization-capable pressures.  We intend to replace the glass vial used to 
hold the 10% CMC every time and its position is related to the two micromotors. 
The injection system should be able to place the microbubble in space 
irrespective of how the personnel place the glass vial within a pre-designed holder. 
Therefore, one platform, which connects the stand for the glass vial and the two 
micromotors (one for the polymer tube and one for the cargo tube translation), will be 
necessary. To find the meeting point of two injection tubes, which are connected to the 
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micromotors, the angle between the micromotors and the platform should be fixed. This 
section described the structure of the platform and how the angle of the micromotors was 
quantified. 
3.7.2 Materials and Methods 
3.7.2.1 Materials 
The goniometer (Figure 31a) with a 1/2inch virtual point (Thorlabs) was 
purchased to control the angle of the drug injection tube which will need to be 
determined and fixed for the rest of the microbubbles to be subsequently similar. The 
control range is ±15º for the goniometer.  
Micromotors (CONEX-AG-LS25-27P) were purchased from Newport (Figure 
31b) and both tubes for the polymer and drug injection were attached to these 
micomotors. The control range for the micromotor is ±27 mm. 
1 dram of borosilicate glass vial (VWR) was used for the primary microbubble 
container, and a 1.8 cm thick wood panel was purchased from Home Depot.  
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3.7.2.2 Finding the micromotor angle 
Figure 31 (a) a goniometer for controlling the angle that the cargo tube is inserted 
into the microbubble and (b) a micromotor which is used to move the polymer- and 
cargo-carrying tubes translationally. Adapted from [60, 61].
The wood panel was cut in 5 pieces; two 10x5 inches2, one 5x7 inches2, and two 
1.97x2.75 inches2 to prepare the stand which fits inside the container which will house  
the entire system. First three wood panels were adhered together via glue and became a 
stand with a base (Figure 32a and 32b), which the glass vial is placed in (Figure 32f). 
The sides of the stand enable the micromotors to be attached at an angle (Figure 32e). 
The goniometer and one micromotor for the drug injection were attached via screws. 
Then, both tubes for the polymer and cargo were attached to the each micromotor. These 
two micromotors were placed on the micromotor holders. The glass vial was fixed on the 
base of the stand by its insertion into a hole. Its exact location is not critical as its 
purpose is to simply hold the 10% CMC which will be used to suspend the microbubble 
(a) (b)
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in a precise location in space relative to the micromotors and independent of the glass 
vial. 
Clay was used to quantify the required angles to have the polymer- and cargo-
carrying tubes meet at the same location in space (this will be finely tuned based on the 
goniometer and micromotors). The micromotor supporters (Figure 32e) were cut to 
match the defined angles indicated by the clay.  
3.7.3 Results and discussion 
The measured angles of clay were quantified via a protractor at 16.27° for the 
polymer-carrying tube and 11.51° for the cargo-carrying tube. The length of each side of 
the micromotor supporters (Figure 32e) were around 7.5cm. After we assembled every 
component both tubes met at the same location, irrespective of the exact placement of 
the glass vial. The goniometer operation was necessary to inject drug exactly into the 
middle of the microbubble. The glued stand was sturdy enough to hold the weight of 
both micromotors. 
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Figure 32. Assembly of the wood stand’s (a) walls (b) base (c) micromotors to 
translationally move the polymer- and cargo-carrying tubes (d) a goniometer to 
control the precise injection of the cargo within the microbubble (e) angled wood 
stands for attaching the micromotors to the walls and (f) a sample of a glass vial. 
(a) 
(b) 
(c) (d) (c) 
(f) 
(e) 
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3.7.4 Conclusion 
For the repeatability of microbubble formation, it is crucial to have consistent 
and automated parameters, to the extent possible.  
The flexibility of the clay facilitated the quantification of the angles needed for the 
micromotor supports (Figure 32e). We observed that both tubes met in the glass vial, 
and the drug injection could be in the middle of the microbubble because the proper drug 
injection position was within the range of the goniometer. 
3.8 ENGINEERING A SELF-CONTAINED LYOPHILIZATION-CAPABLE 
SYSTEM FOR THE MICROBUBBLES 
3.8.1 Introduction 
The automated apparatus is a self-contained system which includes (i) 2 syringe 
pumps, (ii) 2 micromotors, (iii) a goniometer, (iv) a UV bulb and (v) a vacuum pump. 
The syringe pump controls the injection rates and the timing (controlled by a library 
within Python) which will dictate the volume of the microbubbles’ shell and the cargo 
contained therein. The mass of the cargo will be mainly controlled by the concentration 
used and not the volume. The cargo solution will have the pre-determined cryo-
protectant ratios in preparation for the automated lyophilization. In order to create a 
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complete system for microbubble formation, it was necessary to combine the injection 
and UV curing systems to the lyophilization chamber. Therefore, a freeze-drying system 
was designed to accommodate both the polymer and cargo injections and the UV curing 
system.  
The ideal condition for the microbubble lyophilization requires (i) a flash-
freezing reservoir of liquid nitrogen to help retain the cargo within the center of the 
microbubble during the initial stages when the inner cargo bubble could float upwards 
while UV curing is taking place and(ii) and continued overnight lyophilization. In this 
section, we show the design of the vacuum chamber thus far to be used for lyophilization 
of the microbubbles. 
3.8.2 Materials and Methods 
3.8.2.1 Materials 
A 3.5 gallons HDPE round pail were purchased from Grainger. 250 µL Glass 
barrels (Hamilton) are used for forming the microbubble and the cargo. A P-662 female 
luer to microtight assembly (Idex) is the total female part used to connect the tubes to the 
syringe pump barrels. The cargo tube is 12" in length and is a 30 gauge (inner diameter) 
tube (Hamilton). Clear Acetoxy curing RTV Silicone Sealant (Surebond®) was used for 
sealing the plastic container for sufficiently low pressures for lyophilization (the plastic 
container was cut and attached to a metal pot because the vacuum ended up collapsing 
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the bucket and we needed to strengthen the container). Legato 100 syringe pumps (KD 
Scientific) were used for controlling microbubble and drug injection rates.  0.5 dram 
borosilicate glass vial (VWR) was used for the primary microbubble container. 
3.8.2.2 A self-contained lyophilizing system 
The HDPE pail was used for the container which contained the stand, which 
holds two micromotors and the glass vial. The container was cut and glued to a stainless-
steel pot to withstand the low temperature of liquid nitrogen and low pressures required 
for lyophilization. The already functioning lid from the plastic container which contains 
a transparent window, as well as an attachment point for the vacuum was a sturdy 
enough lid that we wanted to use it for the metal pot. We severed the portion that the lid 
attaches to and attached the metal pot thus the original lid and its plastic attachment 
portion was on the metal pot. Every leaking hold, which air could pass through, in the 
bucket and the lid was sealed using silicone sealant. 
The stand, which was described in section 3.7, is able to be placed within this hybridized 
plastic-metal container.  
3.8.3 Results and discussion 
By applying the lyophilizing-capable vacuum (Figure 33), it was confirmed that 
the bucket was completely sealed using silicone sealant. Epoxy glue was intended to be 
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used for the sealing of the container initially but was found to be insufficient. The epoxy 
glue, however, was sufficient in attaching luer locks and tubes due to the epoxy glue 
resistance to chloroform.  Both tubes for forming the microbubble and injecting the 
cargo can now be theoretically injected into the glass vial, which can contain 10% CMC. 
Figure 33. The design of the self-contained lyophilization system for microbubble 
formation. 
This system has not been fully tested and we expect there to be a great deal of 
troubleshooting left for ensuring that this setup is kinetically controlled via LabView. 
The user interface is being built and automated by Whitney Souery, an undergraduate in 
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our lab. Whether this is actually capable of lyophilizing the microbubbles has not been 
able to be tested to date. 
3.8.4 Conclusion 
The container size is sufficiently large to contain every component needed for 
this system. How the liquid nitrogen flow into a secondary container is still yet to be 
determined. Furthermore, it is likely that we may need to have the glass vial protrude 
(yet still be sealed for lyophilization purposes) through the bottom of the container and 
into the liquid nitrogen. We are hoping this will not be required and have chosen a low-
pressure-withstanding pot that will also facilitate thermal conduction for faster freezing 
times of the microbubble. If we need to slow down the process of freezing to not break 
internal components, this will be accomplished.  We have confirmed that the hybridized 
pot is capable of withstanding the lyophilizing-capable vacuum. We need to have wires 
coming through the container, while still being sealed off to ensure the pressure is low 
enough for the sublimation process during lyophilization. All of this needs to be further 
investigated. Our goal is controlling every operation, such as microbubble and cargo 
injection, UV curing, and lyophilization using Labview and Python. 
Through this automation system, we believe that microbubble fabrication will be 
more accurate and precise, and the microbubble physicochemical properties will be 
reliable and repeatable. 
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4 ENGINEERING CARGO RELEASE TIME OF THE MICROBUBBLES 
4.1 QUANTIFY HOW DIFFERING MOLECULAR WEIGHTS OF PCL AFFECT 
RELEASE TIME OF THE MICROBUBBLES 
4.1.1 Introduction 
The release from PCL microparticle depends on the molecular weight, molecular 
weight distribution, and crystallinity. Such parameters affect the cargo entrapment and 
the structural stability of the microparticle. The kinetics of the cargo release can be 
controlled by not only hydrophobicity but also molecular weight of these polymers. 
He, et al. produced microparticles with mPEG (MW 5kDa) and PCL (MW 
20kDa) microparticles by double emulsion evaporation method and achieved 
approximately 20% more drug release when compared to plain PCL (MW 25kDa) after 
42 days [62]. Considering this experiment, release of cargo is mainly due to erosion of 
polymers within the aqueous phase. However, Jeong, et al. reported that the main reason 
which dictates the release profile for the cargo is the cargo diffusion from amorphous 
regions of the microparticle [63]. Here we investigate the role of molecular weight of 
PCL within our microbubbles. 
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4.1.2 Materials and Methods 
4.1.2.1 Materials 
Synthesized PCLTA, PCL (average Mn 14 kDa and 45 kDa) (Sigma Aldrich), 
and 2hHydroxy-2-methylpropiophenone (photoinitiator) (TCI AMERICA) were used for 
PCL/PCLTA microbubbles. Legato 100 Syringe Pump (KD Scientific) was used for the 
microbubble injection. 0.5 dram borosilicate glass vials (VWR) were used for 
microbubble container. BSA-CF488 dye conjugates (Biotium) was used as the cargo. 
4.1.2.2 Fabrication of different molecular weights of PCL/PCLTA microbubbles 
14 kDa and 45 kDa PCL was dissolved in chloroform and the concentration was 
held at 800 mg/mL for forming the microbubble. This PCL solution was mixed with 
PCLTA as 1:3 volume ratio in order to solidify the PCL microbubble shell using chain 
entanglements with lower molecular weight PCL which had terminal acrylate groups, 
enabling UV curing. 1 µL of photoinitiator was added (0.05% final concentration). The 
polymer was loaded within the 250 mL glass barrel and the microbubble injection rate 
was controlled by the syringe pump at 0.5 µL/sec for 10 seconds.  
250 µL of PBS was added to BSA-CF488 stock, and the concentration was 4 
mg/mL. 12.5 mg of CMC was added to this cargo solution, so 5% (w/v) CMC BSA-
CF488 cargo solution was prepared. This cargo was injected into the formed 
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microbubble using 34 G needle, then the microbubble was cured under UV light for 10 
minutes. After confirming the microbubble was cured by confirming the hardness with 
pipette tips, the microbubbles were frozen in liquid nitrogen for 20 minutes and 
lyophilized overnight.  
After lyophilizing, microbubbles were washed and soaked in 500 µL of PBS. The 
PBS solution was collected and analyzed for the fluorescence intensity every 2 days. 
4.1.3 Results and discussion 
14 kDa PCL/PCLTA microbubbles resulted in two separate bolus releases on day 
2 and day 6 (Figure 34). The day 2 bolus is likely due to the presence of the fluorophore 
on the outer surface which has a greater propensity to partition into the organic phase 
(the cargo escaped as the cargo injecting tube was removed from the liquid shell of the 
microbubble.  There were several failures involving premature release of the cargo by 
the temporary conduit created when removing the cargo injecting tube. This escaped 
cargo was dissolved in the outer 10% CMC solution and adsorped and partially was 
absorbed into the shell of the microbubble, according to confocal microscopy. The first 
release was the cargo from the microbubble surface which escaped. After degradation of 
the microbubbles over 6 days, microbubbles showed a second release from the internal 
cargo bubble. The released amount of the second bolus was less than the first release 
amount because the amount of drug in the 10% CMC was more than was actually 
injected into the microbubble. We will be optimizing this further. 
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Figure 34 BSA-CF488 Release Profile from 14 kDa PCL/PCLTA. 
45 kDa PCL/PCLTA microbubble also showed an initial bolus release on day 2, 
similar to the previous microbubbles, confirming this is likely independent of the wall 
thickness of the microbubble (Figure 35). The release of the cargo on day 2 was for the 
same reason as the 14 kDa PCL/PCLTA microbubbles. The second bolus was later than 
14 kDa PCL/PCLTA microbubbles. Higher molecular weight polymers have longer 
chains, and thus can entrap the cargo longer than lower molecular weight microbubbles 
due to chain entanglement.  
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Figure 35 BSA-CF488 Release Profile from 45 kDa PCL/PCLTA. 
4.1.4 Conclusion 
Two different molecular weight of microbubbles showed different release 
profiles. Both microbubbles burst twice, and the first burst was on day 2. However, the 
second burst was on day 6 for 14 kDa PCL/PCLTA and on day 14 for 45 kDa 
PCL/PCLTA (release profile is ongoing). The first burst of the drug, which was 
dissolved in 10% CMC solution, was released from the surface of microbubbles. The 
second burst of the drug was from the inside of the microbubble. 45 kDa PCL/PCLTA 
has longer chain and erosion takes more time than 14 kDa PCL/PCLTA. Due to their 
molecular weight difference, they have different release profile for the second release. 
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Through this work, we observed that increased molecular weights result in longer 
release profiles. Generally, there is a period from one week to a few months or a year 
between vaccine administrations. For the single injection vaccine, we can control the 
burst time by controlling the molecular weight of the microbubbles, we could use 
surface eroding polymers, and we could use thicker shells. The next chapter describes 
the correlation between the shell thickness of the microbubble and the release time. 
4.2 QUANTIFYING HOW VARYING THE MICROBUBBLES’ THICKNESS OF 
THE SHELL CONTROLS THE RELEASE TIME 
4.2.1 Introduction 
The release kinetics is highly dependent on the cargo encapsulation method. 
Single/double emulsion solvent evaporation technique distributes the cargo throughout 
the microparticles. Therefore, the diffusion of the cargo through the polymeric bulk have 
a greater contribution to the release kinetics than the polymer degradation/erosion [63]. 
It is highly probably that there are many diameters within a microparticle itself, in the 
context of double-emulsion-based microparticles. Thus, the conventional encapsulation 
method leads to a continuous release of cargo instead of bolus release, unless the 
catastrophic failure of the microparticles can be taken advantage of in order to achieve a 
secondary burst as was discussed earlier. 
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Since the cargo was encapsulated into the microbubble by injection, a bolus 
release profile was expected. Therefore, the release kinetics depends on the 
degradation/erosion of this shell and the cargo diffusion through the polymeric shell as 
well.  In this chapter, the influence of microbubble’s shell thickness on the release time 
was analyzed. Different cargo amounts were injected to the PCL/PCLTA microbubbles, 
so the polymeric shell is thicker to a smaller cargo volume and thinner with a bigger 
cargo volume. 
4.2.2 Materials and Methods 
4.2.2.1 Materials 
Synthesized PCLTA, PCL (average Mn 45 kDa) (Sigma Aldrich), and 2-
hydroxy-2-methylpropiophenone (photoinitiator) (TCI AMERICA) were used for 
PCL/PCLTA microbubbles. Legato 100 Syringe Pump (KD Scientific) was used for the 
microbubble injection. 0.5 dram borosilicate glass vials (VWR) were used as the primary 
microbubble container. BSA-CF488 dye conjugates (Biotium) was used as the model 
antigen for detection purposes. 
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4.2.2.2 Fabrication of PCL/PCLTA microbubbles with different shell thickness 
45 kDa PCL was dissolved in chloroform and the concentration was held at 800 
mg/mL. This PCL solution was mixed with PCLTA as 1:3 volume ratio to enable curing. 
1 µL (0.05% final concentration) of the photoinitiator was added. The polymer was 
loaded to the 250 µL glass barrel and the microbubble injection rate was controlled by 
the syringe pump at 0.5 µL/sec for 10 seconds.  
250 µL of PBS was added to BSA-CF488 stock, and the concentration is 4 
mg/mL. 12.5 mg of CMC was added to this cargo solution, so 5% (w/v) CMC BSA-
CF488 cargo solution was prepared. 
The microbubbles were divided into two groups depends on the injected cargo 
volume. The cargo volume was controlled by the syringe pump. The smaller cargo 
volume would thus result in a thicker microbubble shell, and a larger cargo volume 
would result in a thinning of the microbubble shell. 
The smaller cargo volume was injected for 2 seconds at a 0.5 µL/sec rate. The 
large cargo volume was injected for 5 seconds at the same rate. The microbubble was 
cured under UV light for 10 minutes. After confirming the microbubble was cured 
(similarly to the way we described previously), the microbubble was frozen in liquid 
nitrogen for 20 minutes and lyophilized overnight.  
After lyophilization, the microbubble was washed and soaked in 500 µL of PBS. 
The PBS solution was collected and the fluorescence was analyzed every 2 days. 
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4.2.3 Results and discussion 
The release of the cargo on day 2 was for the same reason as the different 
molecular weight release study (Figure 36). Since the microbubble for the release study 
with different shell thickness is formed with 45 kDa PCL/PCLTA, the second burst will 
be later than 14 kDa PCL/PCLTA microbubbles of the different molecular weight 
release study. 
Figure 36 BSA-CF488 Release Profile two from different shell thickness 
PCL/PCLTA microbubbles. 
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4.2.4 Conclusion 
Thicker shell microbubble causes more time to degrade the shell, and thus can 
entrap the cargo longer than thinner shell microbubbles. We expect to observe later 
second burst from thick shell microbubble. 
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5 QUANTIFY STABILITY OF HIV AND HEPATITIS B ANTIGENS 
5.1 QUANTIFY HOW THE HIV GP120/41 AND HBSAG AYW ANTIGENS ARE 
STABLE IN TIME IN AN AQUEOUS ENVIRONMENT VERSUS IN A 
CRYO-PROTECTANT CONTEXT AT VARYING TEMPERATURES 
5.1.1 Introduction 
Among many factors, temperature, alongside with hydrolysis, is a crucial factor 
which affects protein stability. Fatunmbi, et al. showed that the avian influenza virus 
maintained its stability without any loss for 42 hours at -20 ºC and -196 ºC [64].  
The function of cryo-protectants is also critical for stabilizing the structure and, 
hence the function, of the protein. Trehalose is one of a number of saccharides which can 
be used as a cryo-protectant and is arguably the most used cryo-protectant amongst the 
saccharides (other examples include, sucrose). The exact mechanism as to what degree 
saccharides absorb water which is retained even throughout the lyophilization process 
[65]. It is for this reason, that the saccharides help protect the function of the protein. 
Also, the protein is more likely to be denatured if the proteins interact with themselves; 
hence having many saccharides present causes the protein to mainly interact with the 
less-denaturing saccharides (in comparison to other proteins. Generally speaking, cryo-
protectants are commonly used in high molar ratios in comparison to the antigen being 
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protected; the excess molar ratio is on the order of 100s to 1000s of times more than the 
antigen.  
To evaluate the protein stability in the microbubble, the functionality of the 
antigen is analyzed using an enzyme-linked immunosorbent assay (ELISA). This data is 
compared to the control antigen which has been stored properly and is considered to be 
non-degraded; in this way percent functionality retained is able to be quantified. Using a 
calibration curve, the mass of the remaining functional antigen in time can also be 
quantified. 
In this section, the control antigen was analyzed in various conditions so that we 
are able to know how well our microbubbles are capable of protecting antigen (in the 
presence and in the absence of a cryo-protectant) at differing temperatures and time 
points. To examine the effects of temperature, the antigen, functioning as a negative 
control was placed at three different temperatures in PBS; 4 ºC, room temperature and 
37 ºC, in aqueous environment. Also, to identify the role of the cryo-protectants, 
trehalose was added to antigens, and subsequently lyophilized. The functionality of the 
mixture was analyzed at various time points and these results are considered the best-
case scenario, or in other words the positive control. By varying the trehalose 
concentration, optimized concentrations for the enhancement of the antigen functionality 
was identified. 
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5.1.2 Materials and Methods 
5.1.2.1 Materials 
Coating buffer (ab210899), Recombinant HIV-1 gp120 + gp41 protein 
(ab49054), Anti-HIV-1 gp120 antibody conjugated to horseradish peroxidase (HRP) 
(ab53840), Anti-Hepatitis B Virus Surface Antigen (Ad/Ay) antibody-HRP (ab34553), 
and 450 nm Stop Solution for Tetramethylbezidine (TMB) Substrate (ab171529) were 
purchased from Abcam. HBsAg preS2 recombinant protein (HBS-870-005P) 
(eEnzyme), Non-fat dry milk (Andwin Scientific), and 1-Step™ Ultra TMB-ELISA 
Substrate Solution (Thermo scientific) were other material for ELISA. Trehalose (Acros 
Organics) was used for cyro-protectant. 
5.1.2.2 ELISA protocols 
HBsAg ayw antigen was diluted in a coating buffer as 10 µg/mL and loaded on 
the 96 well plate. Serial dilution of half concentration occurred, so each well has 50 µL 
of antigen solution. The plate was incubated for 2 hours at room temperature on the 
400rpm plate shaker. After incubation, the plate was washed three times using 300 µL 
PBS for 5 minutes on the 400 rpm plate shaker. 300 µL of 5%(w/v) nonfat dry milk 
solution was loaded and incubated overnight at 4 ºC for preventing non-specific binding 
of the antibody. Blocking solution washed twice with same methods of antigen washing. 
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Anti-Hepatitis B Virus Surface Antigen (Ad/Ay) antibody-HRP conjugates was diluted 
as 1:400 and loaded 100 µL. After 2 hours incubation at room temperature, the plate was 
washed three times with same methods of antigen washing. 100 µL of TMB solution 
was loaded and incubated for 15 minutes at room temperature by covering with foil. 100 
µL of stop solution was added and the absorbance was read at 450 nm after 10 minutes 
from stop solution loading.  
The same protocol was applied for HIV-1 gp120/41 ELISA except 1:800 dilution 
(1.25 µg/mL) of antigen and 2 hours of blocking. 
5.1.2.3 Antigen stability without trehalose 
Both HIV-1 gp120/41 and HBsAg ayw antigens were diluted in coating buffer as 
80 µg/mL. The antigen solution was aliquoted as the same volume in nine microtubes.  
Microtubes were placed at 4 ºC, room temperature, and 37 ºC. Antigen samples were 
collected and frozen on days 4, 7, 14 and 21. After collecting day 21’s samples, the 
functionality of every antigen was analyzed by ELISA. 
5.1.2.4 Find optimized trehalose concentration 
0.5 M of trehalose solution was prepared by adding 0.1797 g of trehalose to 1050 
µL of coating buffer. Six different concentration of trehalose solutions were prepared 
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from 5x10-1 M to 5x105 M solution using a 10x serial dilution. 10 µg/mL of both antigen 
solutions were prepared by diluting the antigen stock using various trehalose solutions. 
Antigen solutions were placed at 37 ºC oven after aliquoting. The functionalities of both 
antigens (HIV-1 gp120/41 and HBsAg ayw) were analyzed on day 4 using ELISA. 
5.1.2.5 Antigen stability with Trehalose 
80 µg/mL of 625 µL of antigen solutions were prepared by diluting antigen stock 
using coating buffer. 17.11 g of trehalose was added to the antigen solutions for creating 
a 0.5 M trehalose solution. The antigen within the trehalose solution was aliquoted to 36 
microtubes and lyophilized overnight. Microtubes were placed at 4 ºC, room 
temperature, and at 37 ºC. Antigen samples were collected and frozen on days 4, 7, 14 
and 21. After collecting day 21 samples, the functionality remaining of the antigens with 
varying conditions were analyzed by ELISA. 
5.1.3 Results and discussion 
5.1.3.1 ELISA 
After many trials, the ELISA protocol was finalized. Casein, 1%, 3%, 5% BSA, 
and 1%, 3% nonfat dry milk solutions were not sufficient in terms of preventing non-
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specific binding. The blank wells which only coated with PBS indicated a high 
background even after blocking with casein, BSA, and low concentrations of nonfat dry 
milk solutions. Also, the incubation time of the blocking buffer appeared to not affect 
the results. 2 hours at room temperature and overnight at 4 ºC blocking with 5%(w/v) 
nonfat dry milk solution did not show any difference in decreasing the excessively high 
background as well. When loaded solutions were removed from the plate at each step, 
tapping the plate was preferred as it helped avoid disrupting the results by mechanical 
disruption caused by the pipette during the aspiration process.  
Among 1:200 to 1:1000 antibody dilutions, 1:400 dilution for HBsAg ayw 
antibody and 1:800 dilution for HIV-1 gp120/41 antibody was sufficient in decreasing 
the excessively high background which could then be used as the calibration curve. 
Absorbance showed a linear trend between 2 and 10 µg/mL of antigen concentrations 
(Figure 37). 
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Figure 37. ELISA calibration curve of (a) HIV-1 gp120/41 (b) HBsAg ayw. 
5.1.3.2 Antigen stability without Trehalose 
HIV-1 gp120/41 antigen samples were collected and analyzed at weeks 1, week 
2, and week 3 via ELISA. HIV-1 gp120/41 underwent loss of functionality as the weeks 
progressed. Also, the antigen formulations which were stored at higher temperatures 
indicated an enhanced loss of functionality due to thermal degradation (and also an 
increase in the hydrolysis due to an increase in water molecules’ thermal energy levels. 
After 3 weeks, the functionality of HIV-1 gp120/41 reduced approximately 70% for all 
the conditions, regardless of the storage temperature. This means that HIV-1 gp120/41 
antigens are susceptible to fast thermal degradation, even at 4 ºC. After 3 weeks, the 
functionality at 37 ºC, room temperature, and 4 ºC was reduced to 37%, 44%, and 48%, 
respectively.  
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The remaining mass of antigen which its percent functionality remaining was 
quantified, compared to the control (zero degradation – stored at -20 ºC) on days 4 and 
day 7. This indicated that there was a continual decrease in the HBsAg ayw antigen 
functionality as a function of time, according to the figure 38.  Also, the degree to which 
higher storage temperatures resulted in faster decrease in functionality was quantified; 
this shows the high influence of thermal conditions on antigens’ stabilities. On day 4, the 
samples which were maintained at 4 ºC retained 90% of function, whereas samples at 37 
ºC retained only 41% of its functionality. After 3 weeks, the functionalities at 37 ºC, 
room temperature, and 4 ºC were reduced to 29%, 54%, and 80%, respectively.  
Figure 38. Antigen stability without trehalose. (a) mass of HIV-1 gp120/41, (b) 
functionality of HIV-1 gp120/41, (c) mass of HBsAg ayw, and (d) functionality of 
HBsAg ayw. 
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The functionality seems to be directly related to the amount of antigen available, 
since the less degraded samples present higher functionality signals (i.e. samples kept at 
4 ºC had a lower functional loss). The upcoming results with trehalose in the context of 
the microbubble (these endeavors are currently ongoing within the lab) are expected to 
show attenuated loss of functionality due to the cryo-protectant effect.  
5.1.3.3 Quantify optimized trehalose concentrations 
The functionality of both antigens, HBsAg ayw and HIV-1 gp120/41, were 
increased with increasing trehalose concentrations (Figure 39). Even though it is 
apparent from these two graphs that there is a significant increase of functionality 
between 5x10-3 M and 5x10-4 M trehalose, both antigens’ HBsAg ayw and HIV-1 
gp120/41 functionalities kept increasing and reached 99.05% and 99.78% at 0.5 M 
trehalose, respectively. Because both antigens demonstrated almost 100% of 
functionality on day 4, trehalose concentrations of 0.5 M were used as the best-case 
scenario, or positive control (which is our gold standard of comparison). 
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Figure 39. Correlation between antigens functionality and trehalose concentrations 
(a)HBsAg ayw (b) HIV-1 gp120/41. 
5.1.3.4 Antigen stability with Trehalose at 0.5 M 
In the presence of trehalose, HIV-1 gp120/41 antigens were more stable (Figure 
40a and b). After 3 weeks, the functionality at 37 ºC, room temperature, and 4 ºC was 
reduced to 39%, 46%, and 51% in presence of trehalose, respectively. 2-3% of 
functionality was increased when it was compared to the functionality in the absence of 
trehalose.  
The functionality of HBsAg ayw with trehalose was better than the functionality 
of HIV-1 gp120/41 (Figure 40c and d). After 3 weeks, the functionality at 37 ºC, room 
temperature, and 4 ºC was reduced to 59%, 60%, and 82%, respectively. Thus, trehalose 
was shown to have a thermal protective or thermal stabilizing effect for our antigens.  
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Figure 40 Antigen stability with trehalose. (a) mass of HIV-1 gp120/41, (b) 
functionality of HIV-1 gp120/41, (c) mass of HBsAg ayw, and (d) functionality of 
HBsAg ayw. 
5.1.4 Conclusion 
The ELISA protocols for each antigen was optimized after many trials. The high 
background was resolved using 5% non-fat dry milk solution, and the blocking time did 
not affect the results after 2 hours. The proper antibody dilution ratios were 1:400 for 
HBsAg ayw and 1:800 for HIV-1 gp120/41, respectively. From 2 µg/mL to 10 µg/mL 
the results showed a linear calibration curve. 
The extent to which both antigens lost their functionality with increasing 
temperature as time proceeds was quantified. The loss of functionality was significantly 
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lower at 37 ºC compared to the colder temperatures. After three weeks, HBsAg ayw lost 
63% of the functionality and HIV-1 gp120/41 lost 71% of the functionality at 37 ºC.  
Trehalose enhanced the stability of both antigens. The stability of antigens increased 
with the trehalose concentration. On day 4, HBsAg ayw and HIV-1 gp120/41 showed 
99.05% and 99.78% of stability with 0.5 M trehalose, respectively. Therefore, 0.5 M of 
trehalose was used to examine the antigen stability with the cryo-protectant. 
While holding the temperature constant while varying trehalose, both antigens 
showed better functionality than without trehalose. HIV-1 gp120/41 lost 61% of the 
functionality and HBsAg lost 41% of it at 37 ºC. Even though both antigens’ stabilities 
were enhanced, HBsAg ayw showed a greater enhancement than the HIV-1 gp120/41 
antigen. This result may be explained by the fact that HIV-1 gp120/41 antigens mutate 
too fast, in comparison to when they are stabilized with trehalose. 
The stability of antigens and the function of trehalose as a cryo-protectant were 
described in this work and will serve as the positive and negative controls or the gold 
standards for our microbubble application to delivery these specific antigens. In future 
work, we can apply trehalose also in the microbubbles and compare to this stability data 
but there will be a tradeoff between how many microbubbles will need to be delivered as 
the trehalose concentrations are increased because space that the antigen within the 
microbubbles will decrease due to the presence of more trehalose cryo-protectant. 
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6 DNA- AND AMINO ACID-BASED VACCINE DELIVERY SYSTEM 
AGAINST INFECTIOUS DISEASES* 
6.1 INTRODUCTION 
With the continual improvement of DNA sequencing technology, we can better 
understand key conserved sequences which can be transcribed and translated into 
antigens and discover or engineer sequences which may be used for protection (i.e., 
TSOL18[66-68]). Via DNA recombinant technology we are able to mass produce 
nucleic acid code which can be directly delivered and can be subsequently processed and 
displayed by antigen presenting cells (APC)s for eventual seroconversion by the 
vaccinee’s own transcription and translation machinery. Furthermore, via DNA 
recombinant technology peptides or proteins or subunits thereof can be mass produced in 
cells (i.e., E. coli and yeast) for vaccine manufacturing.  
Many peptide and protein vaccines require a cold chain delivery (i.e., Recombivax 
HB®, Engerix-B®), whereas DNA vaccines are considered more thermostable (Figure 
41:(1)). The vaccine may be uptaken intracellularly via endocytosis (Figure 41:(2)) [69] 
__________________________ 
*Adapted with permission from: DeMuth, et al. Adv Healthc Mater. 2014,  3, 47-58. Copyright © 2017
John Wiley & Sons, Inc.; Dutta, et al. J. Mater. Chem. B. 2017, 5, 4487–4498. Copyright © 2017 RSC; 
Santini, et al. Nature 1999, 397(6717) 335-8. Copyright © 2017 Macmillan Publishers Limited. 
*Adapted from: McHugh, et al. Science. 2017, 357, 1138–1142. Copyright © 2017 AAAS
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or interact extracellularly via the toll-like receptor (TLR)2/4 pathway, resulting in the 
expression of pro-inflammatory cytokines and chemokines (interleukin (IL)-8/10, TNFα) 
(Figure 41:(3)). Plasmid DNA can either be randomly encapsulated by the nuclear 
envelope during mitosis or actively transported to the nucleus via nuclear localization 
signals (i.e. DNA-targeted sequences – SV40 [70]) (Figure 41:(4)).The proton sponge 
effect plays an important role for the plasmid DNA to escape the endolysosomal 
degradation pathway (Figure 41:(5)). Via the cytosolic degradation pathway, the amino 
acid-based antigen is degraded into peptides and presented by MHC II extracellularly to 
CD4+ T cells (Figure 41:(6)) [71]. Via the proteasome degradation pathway (ubiquitin-
proteasome pathway), antigens become peptides, which interact with CD8+ T cell 
recptors (TCR)s via MHC I extracellularly, post-maturation which takes place mainly 
within the Golgi apparatus (Figure 41:(7)). DNA vaccines may contain unmethylated 
CpG sequences which function as a pathogen-associated molecular pattern (PAMP) and 
can activate TLR9 in the endosome, eventually releasing IL-4 and IFNa (Figure 41:(8)). 
The immune response can be Th2-biased (antibody-mediated) or Th1-biased (cell-
mediated), depending on the cargo, the delivery vector, the adjuvant, and the context of 
antigen presentation (Figure 41:(9)) [72].  
This article will discuss DNA- and amino acid-based vaccine delivery systems 
against infectious diseases, with an emphasis on polymeric-based applications. More 
specifically we will discuss: a brief historical perspective of vaccines and vaccine 
classifications; the engineering of kinetics for vaccine delivery; enhancing the duration 
of protection via non-kinetic approaches; enhancing the stability of cargo; the state of the 
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art in DNA-based vaccines; manufacturing and engineering DNA; the stability and 
safety of DNA vaccines; plasmid delivery; controlling gene expression via plasmid 
engineering and gene circuits; overcoming immunogenic issues of DNA-based vaccines; 
examples of DNA-based vaccine commercial successes; as well as give a summary of 
the state of the field, and report our perspective on future directions.  
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Figure 41 DNA- and amino acid-based vaccines. (1) Storage/transport via cold 
chain for amino acid-based vaccines versus more thermostable DNA-based 
vaccines; (2) endocytosis; (3) extracellular activation, through TLR2/4, resulting 
in the expression of pro-inflammatory cytokines and chemokines (IL-8/10, 
TNFα); (4)  plasmid DNA uptake; (5) Proton sponge effect for DNA-based 
vaccines (6) the cytosolic degradation pathway, resulting in MHC II antigen 
presentation to CD4+ T cells; (7) the proteasome degradation pathway and the 
eventual MHC I antigen presentation to CD8+ T cells; (8) CpG sequences 
activating TLR9 and the resulting in IL-4 and IFNa release; (9) Th2-biased 
(antibody-mediated) and Th1-biased (cell-mediated) responses, depending on the 
context of antigen presentation.[72] (APC, antigen-presenting cell; CCR5, C-C 
chemokine receptor type 5; CpG DNA, DNA fragment containing cytosine 
nucleotide followed by guanine nucleotide; CTL, cytotoxic T lymphocyte; ER, 
endoplasmic reticulum; IFN, interferon; Ig, immunoglubulin; IL, interleukin; 
MHC, major histocomppatibility complex; TCR, T cell receptor; Th, T helper 
cell; TNF, tumor necrosis factor; TRL, toll-like receptor; VLP, virus-like 
particle). 
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6.1.1 From variolation to vaccine: a historical perspective 
Variolation itself is a crude method for introducing the variola virus intentionally 
by often simply scratching the scabs and pus of an infected individual into another to 
provide future protection. The variola virus, also known as smallpox, causes symptoms 
of fever, papules, and pustules. The Greek historian Thucydides reported a protective 
effect in smallpox survivors around 400 B.C.[73] Around 900 A.D., historical records 
describe nostril inoculation with the dry matter of smallpox pustules in China [74]. The 
Chinese book, “Great Herbal” describes the use of “powdered cow ice into child’s nose” 
in 1597. According to historical records, variolation was commonly practiced in India, 
Africa, and China before the 17th century. Variolation inevitably led to many fatal 
infections but also provided protection against smallpox in many cases [75]. In Europe, 
the first records show that variolation was first used in Denmark, and then started 
spreading from Turkey in the 18th century. The development of variolation in Europe 
allowed conquistadors to use smallpox as a biological weapon to reduce the population 
of Native Americans during conquests, as variolation practices in the New World were 
less common [73]. 
The variola virus by many is considered the first infectious disease eradicated by 
a first-generation vaccine. Edward Jenner observed that a dairy maid had cowpox lesions 
on her finger and inoculated it into an 8-year-old neighbor boy, James Phipps who 
subsequently contracted cowpox and recovered in just a few days. Latter Jenner then 
exposed James Phipps to smallpox and the young boy was protected due to cross-
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reactivity. Jenner published the result in the book “An Inquiry into the Causes and 
Effects of the Variolae vaccinae, a disease discovered in some of the western counties of 
England, particularly Gloucestershire and known by the name of Cow Pox”. Vacca 
means cow, and vaccinia means cowpox in Latin, from which the word vaccine 
originates. According to the statistics of Jurin, the average mortality rate by smallpox 
was at one point 16.5% [76, 77]. Smallpox spread throughout European countries in the 
18th century, and caused more than 1/3 of all blindness cases and killed around 400,000 
people every year [78]. Smallpox was officially declared eradicated in 1980.  
Another historical example of greatly reducing rates of infection is poliomyelitis, which 
was spurred by the beginnings of cleaner water, as people were exposed to a lesser 
degree; thus they were no longer naturally immune [79]. Jonas Salk`s inactivated 
poliovirus vaccine (IPV) exhibited 80-90% effectiveness in preventing paralytic 
poliomyelitis supported by a large-scale clinical trial, comprising 1.8 million elementary 
school-aged children (1st to 3rd graders) [80]. Meanwhile, Herald Rea Cox and Albert 
Sabin were describing an effective and safe live-attenuated Oral Poliovirus Vaccine 
(OPV) between 1957 and 1959, following the guidelines established by the WHO Expert 
Committee on Poliomyelitis [81, 82]. By the year of 1961, Sabin’s OPV type 3 vaccine 
was officially recommended by the U.S. Surgeon General and more than 50 million were 
immunized [82]. In 1988, prior to the World Health Organization (WHO) announced the 
resolution to eradicate Poliomyelitis [83].  In September 2015, OPV type 2 was removed 
from the trivalent vaccine, given how rare OPV type 2 infections occur. The type 2 
serotype of OPV will now solely be used for outbreaks [84]. Recently, several countries 
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have started using Salk`s IPV vaccine (type 2 strain) as a means to further protect 
children born after April 2016 [85]. 
6.2 AN OVERVIEW OF VACCINE CLASSIFICATIONS 
Table 1 Generalized qualitative comparisons of vaccine classifications. Please note 
that a few exceptions may contradict the generalized qualitative comparisons. 
Administration routes, advantages and disadvantages in the contexts of production, 
immunogenicity, biosafety, transportation/storage, and also examples of 
commercialized DNA- and amino acid-based vaccines for each vaccine 
classification are tabulated.  
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For convenience to the readers, a brief overview of vaccine classifications is 
discussed (Table 1). 
6.2.1 Live attenuated vaccines 
Live attenuated vaccines (LAV)s are a weakened form of the wild viruses or 
bacteria, which have a near zero probability of causing an infection. Although weakened, 
the structural integrity of pathogenic patterns is sufficiently preserved, enabling the 
efficient production of neutralizing antibodies. In particular cases, a virulent strain may 
be continually cultured until a non-pathogenic version arises through genomic mutations, 
reducing virulence. With increasing attenuation, however, seroconversion becomes more 
unlikely as the attenuated version becomes increasingly dissimilar in comparison to the 
wild-type antigen. Commercially available examples of LAVs are Attenuvax® 
(measles), Mumpsvax® (mumps), Meruvax-II® (rubella), Rotateq® and Rotarix® 
(rotavirus), and FluMist® (influenza) (Table 1) [86, 87].  
Despite the biosafety risks, LAVs are easier to prepare and provide effective 
immunization by eliciting strong and long-lasting humoral and cellular immune 
responses. The good immunogenicity of LAVs is related to a simultaneous recognition 
of multiple pathogen patterns. Hence, there is an increasing interest for adjuvants and 
novel delivery systems (e.g., virus-like particle, polymeric microparticles), which are 
attempts of mimicking the immunostimulation provide by LAVs [88-90]. The LAVs 
may have exogenous material due to the production process, such as egg protein, hence 
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the use of a LAV may be contraindicated in cases when the vaccinee may have an 
allergic response. 
6.2.2 Killed or inactivated vaccines 
Killed or inactivated vaccines (IV)s consist of pathogenic microorganisms which 
are partially or completely incapacitated through exposure to heat, high-energy radiation 
(e.g., gamma radiation) or chemicals (e.g., formaldehyde). These treatments can be used 
to induce minor changes in the structure of the antigen, preserving sufficient 
immunostimulatory capacity, and preventing pathogenic reversion. Safety-wise, the IVs  
are safer than LAVs. Moreover, IVs may require a greater amount of antigen and higher 
numbers of booster doses for life-long immune protection when compared to LAVs 
(Table 1). 
Currently, IVs, in conjunction with adjuvants such as polysaccharides (PS) and 
TLR ligands, are intensely studied [91, 92]. IVs are used worldwide for immunizations 
against influenza serotypes. The production capacity achieved 6.372 billion/year in 2005 
[93]. Examples of IVs available on the market include Ipol® (poliovirus), Fluarix®, 
Flublock®, Fluzone® (influenza), Imovax® (rabies) (Table 1) [94-98]. 
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6.2.3 Toxoid vaccines 
Toxoid vaccines are usually obtained from exotoxins released by a toxigenic 
bacterial strain. The toxin undergoes a heat or chemical treatment (e.g., formaldehyde 
treatment to produce the Tetanus toxin) in order to achieve a toxoid form with an 
acceptable toxic level for vaccine utility (Table 1). Therefore, the toxoid cannot induce a 
pathogenic condition within the patient, yet must improve the capacity of eliciting the 
antibody-mediated immune response. Generally, therapies against toxoids are antibody-
mediated, which can be provided to the patient through passive immune therapy (e.g., 
administration of engineered antibodies, maternal antibodies to the fetus during 
pregnancy) [99, 100].  
Toxoid vaccines can be mass-produced via bioreactors. A semi-continuous 
reactor maintains the toxigenicity of the pathogenic bacteria [101]. Tetanus and 
diphtheria toxoid vaccines are commercially available as a single-toxoid or a combined 
toxoid vaccine. Diphtheria and Tetanus vaccines are commonly combined with other 
types of vaccines such as DTaP (Infanrix®, Daptacel®), which includes acellular 
Pertussis as a constituent (Table 1)  [102]. Toxoid vaccines present a low risk for 
infection and side effects but also are associated with immunogenicity. Recent studies 
report enhanced immunogenicity of toxoid vaccines combined with adjuvants such as 
the TLR4 agonist [103]. 
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6.2.4 Unconjugated polysaccharide vaccines 
Unconjugated or plain polysaccharide vaccines are a specific type of subunit 
vaccine (refer to the following section and Table 1) composed by polysaccharides from 
bacterial capsules. Bacterial capsules’ polysaccharides which are highly antigenic can 
serve as the immune target within the vaccine. The risks of contamination and reversion 
are drastically reduced due to the vaccine composition. Polysaccharide vaccines are 
largely used in the immunization against pneumococcal, meningococcal, and typhoid 
diseases. Pneumococcal (PNEUMOVAX®23) meningococcal (Menomune®; Sanofi 
Pasteur, however, recently reported they will discontinue production of their Menomune 
vaccine; they are moving towards a conjugate vaccine replacement which is in phase III 
clinical trials) [104], and typhoid (Typhim Vi®) are examples of polysaccharides 
vaccines (Table 1)  [105]. After vaccine administration, polysaccharide fragments 
interact with MHC II, which leads to a predominantly cellular immune response and 
limited humoral and memory IgG responses [106]. Particularly in infants there is an 
increased risk of infection due to their immature immune system [107].  
6.2.5 Subunit vaccine 
Subunit vaccines present superior safety profiles in comparison to whole-cell 
vaccines since there is no risk of infection or reversion of the microorganism to the 
pathogenic form. Thus, subunit vaccines can be ideal for immunocompromised patients 
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[108]. Despite subunit vaccines having several safety and stability advantages, the 
immunogenicity is often lower than ideal and requires adjuvants and booster doses to 
achieve adequate prophylactic immune responses, providing protection against future 
exposures. Subunit vaccines comprise a sub-portion of the antigen, as opposed to the 
whole microorganism employed for LAV and IV (Table 1). Subunit vaccines are 
generally more stable and more easily stored and transported. For example, Flood, et al. 
[109] reported the development of an H1N1 influenza subunit vaccine stabilized by 
freeze-drying process, which remained stable for 3 years at room temperature and 37 ºC. 
6.2.6 Subunit vaccine - Conjugate polysaccharide 
Because obtaining protective immunity using solely polysaccharides is 
challenging, more potent antigens (commonly a subunit) are commonly conjugated to 
the polysaccharides. For example, it was reported that the 13-valent pneumococcal 
conjugate vaccine elicited a greater functional response in pneumococcal vaccine-naïve 
adults, when comparing the specific antigens within the 23-valent pneumococcal 
polysaccharide vaccine [110]. Haemophilus influenzae type b vaccine (Hib) was the first 
protein-conjugate polysaccharide vaccine produced (1980) [111]. Hib is not given in 
sequential boosters, however, unless patients have had a splenectomy or are 
hematopoietic stem cell transplant recipients. The subsequent success of protein-
conjugated polysaccharides vaccines against meningococcal and pneumococcal 
infections were in 1994 and 1996, respectively [112, 113].  
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In 2011, Avci, et al. [114] reported that T cells are not only capable of interacting 
with peptides on major histocompatibility complexes but also are capable of directly 
detecting the polysaccharide portion of the glycoconjugate. This discovery elucidates, in 
part, the mechanism behind unconjugated polysaccharide vaccines discussed above 
(glycovaccines) and will certainly impact the development of this type of vaccine. 
6.2.7 Subunit vaccine – Non-recombinant 
Regarding the production of non-recombinant subunit vaccines, the pathogenic 
microbes are cultured, disrupted, and the antigen of interest is extracted, purified into 
subunits through a combination of physical separation techniques (i.e., chromatography) 
[115], or chemical modifications, such as base extraction, disulfide reduction (i.e., via 
dithiothreitol or glutathione) [116]. For recombinant DNA-based subunit vaccines, a 
replicating vector (e.g., yeast or bacteria) is transformed with an engineered DNA 
sequence for transcription and translation into a recombinant protein vaccine which can 
then be administered to the vaccinee. 
6.2.8 Subunit – Recombinant: amino acid based-vaccines 
Recombinant protein vaccines are antigen-based synthetic proteins produced by 
recombinant DNA technology. For instance, Hepatitis B recombinant protein vaccine 
(HEPLISAV-B®, FENDrix®) is based on hepatitis B virus surface antigen (HBsAg) and 
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several HIV-1 recombinant protein vaccines are based on surface glycoproteins (gp140) 
[92, 117, 118]. In both cases, recombinant proteins were produced to mimic antigenic 
molecules and used them as immunostimulatory agents for prophylactic therapy. 
Because there is no pathogenic whole-cell or subunit in the recombinant protein vaccine 
formulation, the risk of reversion to virulence is minimized but the immunogenicity is 
inferior [119].  
DNA and protein vaccines share a major part of the production process but vary 
in the immune system eliciting mechanisms (Figure 41). The first step consists in 
inserting the gene of interest (GOI) into the plasmid vector, which follows the 
transformation into the replicating bacteria or yeast. After the replication, the 
recombinant protein is extracted, purified, and prepared as a vaccine. In the case of DNA 
vaccines, commonly the replicating prokaryotic vector is disrupted, the engineered DNA 
is extracted, and purified to produce the final vaccine. After the administration to the 
patient, recombinant protein vaccines are internalized within the host cells, processed to 
antigenic peptides, which elicit the immune system. DNA vaccine must achieve the 
nucleus in order to use the host molecular machinery to promote the transient expression 
of the GOI. After the transcription and translation of the GOI, it is processed to antigenic 
peptides and elicits immune responses. 
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6.2.9 Subunit – Recombinant: DNA vaccines 
In the case of a “DNA vaccine”, the engineered DNA is directly administered to the 
patient and usually with a carrier, where transient gene expression provides the antigen 
of interest. DNA vaccines were introduced in the late 90s, when Wolff, et al. [120] 
injected plasmid DNA intramuscularly in mice. Afterward, Jiao, et al. [121] proposed 
the delivery of DNA plasmid to non-human primates, and Ulmer, et al. [122] described a 
vaccine against influenza using plasmid DNA in mice. The following sections will 
cover: the manufacturing and the engineering of DNA vaccines; the stability and safety 
of DNA vaccines; the kinetics controls for DNA vaccine release; the delivery barriers for 
DNA vaccines; the active nuclear transport for nuclear uptake of DNA; the control of 
gene expression via plasmid engineering and gene circuits; the techniques to overcome 
immunogenic issues of DNA vaccines; and the delivery methods of DNA vaccines in 
pre-clinical and clinical trials. 
6.3 ENGINEERING KINETICS OF VACCINES VIA POLYMERIC METHODS 
Although some LAVs and IVs are known for their favorable immunogenic 
properties and the induction of long-term protection with a single or a small number of 
doses, other vaccines such as toxoid and subunit vaccines generally require a greater 
number of exposures to the antigen compared to LAVs and IVs. However, the 
administration of multiple doses increases the vaccination cost, reduces the coverage 
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capacity, and creates additional obstacles to accomplishing long-term vaccination 
schedules, particularly in developing countries [123]. In this context, the vaccine 
research field is increasingly interested in the development of formulations that require 
fewer numbers of injections or employ delivery systems capable of auto-boosting.  
Polymeric delivery systems’ physicochemical properties can be fine-tuned to 
kinetically control antigen release profiles in order to improve the seroconversion of 
vaccines. The variety of polymers and structural modifications creates a plethora of 
possibilities in designing sustained release systems intended for multiple and long-term 
boost as a single injection. Understanding the structure-activity relationships aids the 
researchers in designing superior drug delivery systems based on rationale, as opposed to 
high-throughput screening. 
The effective generation of memory T cells depends on several stimuli: the antigen 
presentation, co-stimulation, and the presence of inflammatory/danger signals [124]. 
Nolz, et al. [60] demonstrated how the history of antigen exposure can affect the 
number, phenotype, and function of T cells. Multiple vaccine doses (intermittent antigen 
release) can improve the immunogenicity but methodical studies are necessary to 
optimize the immune response for varying the kinetics of prime and/or boosting series, 
in conjunction with the use of adjuvants. On the one hand, the excessive exposure to the 
antigen can lead to a T-cell exhaustion state, in which the effector and memory 
capacities are reduced. In the case of a defective stimulation (i.e. lack of adequate co-
stimulatory/co-inhibitory signals), a T-cell unresponsive state can be observed (T cell 
anergy) [125]. In the case of vaccines that require multiple boosts, T cell anergy 
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induction is a possibility. It is critical to fully elucidate how the kinetics of antigen 
release affects seroconversion for full optimization. 
In terms of engineering kinetics, several studies have developed delivery systems 
for sustained release of the compound of interest [126]. As for vaccines, such systems 
are intended to provide long-term immunization with a single-shot administration, 
especially for toxoid and subunit vaccines. The most common method to control drug 
kinetics involves polymeric systems such as: polyacrylic acid (PAA) [127], poly(β-
amino ester) (PBAE) [128], poly(lactic-co-glycolic acid) (PLGA) [129], poly(methyl 
methacrylate) (PMMA) [130], polycaprolactone (PCL) [131], ethylene vinyl acetate 
polymers [132], chitosan[133], and layer-by-layer (LbL) delivery of various 
combinations of polyelectrolytes [134]. A non-exhaustive list of non-polymeric systems 
include: microchips [135], layered double hydroxide nanoparticles [136], and silica 
particles [137]. 
Polymer-based drug delivery systems have been studied for decades and mainly 
employ biocompatible and biodegradable polymers. For example, Zarrati, et al. [130] 
described the use of a DNA vaccine prepared with PMMA for Leishmania 
immunization. The plasmid DNA vector was encapsulated within the PMMA and 
administered through intramuscular injection, which induced the production of cytokines 
and elicited an antibody response in mice. Titti, et al. [138] employed PMMA-based 
microspheres to deliver the HIV-1 Tat protein and alum as an adjuvant in Rhesus 
macaques. This vaccine design led to a balanced Th1/Th2 response and strong anti-Tat 
humoral response.  
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PLGA is a hydrophobic, relatively biocompatible (has had approved indications by the 
Food and Drug Administration (FDA)) and biodegradable co-polymer which is widely 
employed as a biomaterial for medical use. In the vaccine field, PLGA-based systems 
have been mainly studied with respect to antigen encapsulation and delivery as nano- 
and microparticles due to PLGA’s ability to control degradation, achieved by 
monomeric ratio modulation of the lactides (less hydrophilic) and glycolides (more 
hydrophilic) [139-143]. McHugh, et al. [123] discussed several studies involving 
polymeric single-particle or reservoir boosting systems for vaccine delivery. McHugh, et 
al. also discussed vaccine administration by (1) repetitive injections via boluses, (2)  
single-injections of microparticles that release antigen continuously, and (3) single 
injections of microparticles with programmable pulsatile antigen release. 
DeMuth, et al. [127] described a vaccine design based on silk-tipped and PAA 
pedestal composite microneedles for the transcutaneous delivery of antigen (ovalbumin, 
OVA). The composite microneedle (Fig. 42A) allowed different antigen release 
regimens in a single-administration vaccine. Five minutes after priming, the antigen was 
completely released from the PAA pedestal of the microneedle (Fig. 42B, MN-PAA), 
while the antigen released from the silk tip (MN-silk) took 4 days to to reach 
completion. Moreover, a continuous antigen release was detected up to 14 days from a 
methanol-treated silk tip (MN-MeOH-silk), which demonstrated an improved cross-
linked silk structure. This approach avoided the use of needles, enhanced the 
inflammatory response, and enabled the modulation of the release kinetics of antigens by 
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Figure 42 Polymer-based delivery systems. (A) Silk/PAA composite microneedle 
micrograph (scale bar: 500 µm); (B) OVA release from silk/PAA microneedles 
measured by fluorescence; (C) microfabricated PLGA microparticle before antigen 
dispensing (left, scale bar: 100 µm) and after thermal sealing (right, scale bar: 500 
µm); (D) antigen release in pulsatile kinetics measured by fluorescence; (E) antigen 
distribution in PLGA microspheres submitted to a short (left) and long solvent 
evaporation (right, scale bar: 20 µm) on the evaporation time; (F) different antigen 
release profiles obtained for  short and long solvent evaporation; (G) IPV antigen-
containing PLGA microspheres with 7.5% EPO (left) and 5% EPO/0.4% L-
arginine (right, scale bar: 20 µm); (H) IPV antigen release profile change 
drastically with the microparticle composition; (I) micrograph of the wirelessly 
controlled implantable PLGA microchip before (left) and after (right, scale bar: 50 
µm) the triggering the antigen release; (J) antigen release rate release show well 
defined pulsatile release. Adapted with permission from [5, 127, 144, 145]. Adapter 
from [25]
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chemically altering the microneedle structure. The antigen-specific T cell and humoral 
responses presented 10-fold increases in comparison to parenteral needle administration. 
McHugh, et al. [144] designed an injectable PLGA-based microparticle using 
computer chip-based microfabrication techniques, a picoliter dispenser, in addition to a 
novel cap sealing method using a mask aligner (which is generally used for 
photolithography. With this technology they obtained highly controlled antigen releasing 
profiles (Fig. 42C). The microparticles presented a greatly tunable and sharp antigen 
bolus release observed from four to seventy days (Fig. 42D). The different release 
kinetics were achieved by varying the polymeric chain size (12-200 kDa) and  
lactide:glycolide ratios . Predicting which microparticles were properly sealed, however, 
was a major challenge. 
Dutta, et al. [5] described a dichloromethane and ethanol procedure to control 
antigen distribution in microparticles and how the distribution of antigen throughout the 
particle modified the release profile. However, such solvents are known to denature 
proteins used as antigens which limits the potential applications of the technology. In 
Fig. 42E, the authors show that a short period of ethanol evaporation (left) leads to 
antigen concentrated in the core of the particle. In the case of a long period of ethanol 
solvent evaporation (right), the antigen was found in both the core and the peripheral 
area of the microsphere. With the particles obtained by long solvent evaporation 
demonstrated a greater release rate during days 22 to 42 which is likely due to 
catastrophic failure of the microparticles. Other groups have also demonstrated a second 
burst due to catastrophic failure of PLGA-based microparticles [25]. After the observed 
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release rate increased from days 22 to 42, the cumulative release reached almost 90% 
after 2 months (Fig. 42F).  
Tzeng, et al. [25] achieved a stable and long-term IPV antigen release from 
PLGA microspheres produced with thermostabilizing molecules (e.g., maltodextrin, 
trehalose, sucrose, monosodium glutamate) and Eudragit® E PO (EPO), which likely 
served as a buffer for the acidifying degradation byproducts of PLGA. In Fig. 42G, the 
scanning electron microscope images depict PLGA microspheres with 7.5% EPO (left) 
and 5% EPO with 0.4% L-arginine. The release profiles for IPV serotypes 1, 2, and 3 
drastically change with the addition of L-arginine, which likely helps buffer the internal 
acidification process during the degradation of PLGA microspheres. Furthermore, the 
buffering process was likely responsible for enabling stability and a slower release 
profile (Fig. 42H). Catastrophic breakdown of the microparticles later in the degradation 
process enabled the microparticles to have an additional boosting effect which was 
apparent in a number of the formulations. 
In 2012, Farra, et al. [135] performed the first clinical trial of an implantable 
microchip system for drug delivery controlled by wireless communication which is a 
promising delivery system for sustained release of vaccines. The experiment tested the 
release of anabolic hormones used in the treatment of osteoporosis. The implanted 
device was found to be well-tolerated by the patients. The initial development of the 
controlled microchip delivery system (Fig. 42I (microchip), 42J (release profile)) was 
first reported by Santini, et al. in 1999 [145]. 
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DeMuth, et al. [146] developed a PLGA microneedle vaccine coated with an 
erodible multilayer, which contained protein vaccine (OVA) and an adjuvant, 
monophosphoryl lipid A. Interbilayer-crosslinked multilamellar lipid vesicles (ICMV)s 
produced with dioleoylphosphatidylcholine were used to encapsulate the protein vaccine 
and adjuvant. The anionic ICMVs were intercalated with cationic and biodegradable 
PBAE. The OVA release qualitatively increased from 6 to 24 hours according to 
confocal microscopy, demonstrating the kinetic behavior of the PBAE and ICMV 
degradation.  
The LbL is a surface deposition technique based on electrostatic interactions that 
allow the fabrication of diverse wafer-like drug delivery systems [147]. Using LbL for 
vaccine design holds great potential to produce long-term immunization with 
controllable release profiles. A variety of charged entities have been used for LbL 
including: polymers, charged lipids, polysaccharides for the cationic/anionic 
combination. In the study performed by van der Maaden, et al. [148] inactivated 
poliovirus fragments which were deposited atop microneedles and subsequently covered 
by a cationic polymeric layer made of N-trimethyl chitosan chloride (TMC). This bilayer 
was repeated 10 times to deposit sufficient levels of antigen on the microneedle array, 
which contained 585 ng of viral protein and 700 ng of TMC. The immunization process 
included a prime, followed by a booster at three weeks. The authors demonstrated they 
successfully induced an IPV-specific antibody response.  
A couple of other PLGA-based vaccine developments include a vaccine for 
autoimmune encephalitis, as well as a hydrogel-based OVA vaccine platform. PLGA 
129 
nanoparticles were employed to deliver the subcutaneous vaccine for encephalomyelitis 
autoimmune disease. The PLGA-containing myelin oligodendrocyte glycoprotein 
functioned as the antigen and IL-10 as an adjuvant showed sustained release for 31 days 
[149]. Bobbala, et al. [131] recently described the development of the pentablock  
hydrogel-based vaccine delivery system which employed a pentablock copolymer depot 
loaded with PLGA nanoparticles and an alum adjuvant. They demonstrated control over 
the hydrogel release time by the ratio of PCL and polylactic acid content. Both cellular 
and humoral immune responses were detected in mice and a specific OVA-IgG antibody 
response was observed for 49 days after the injection.  
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6.4 ENHANCING THE DURATION OF IMMUNE PROTECTION USING 
NON-KINETIC APPROACHES 
Table 2 Examples of adjuvants. [91, 92, 117, 118, 150-187] 
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Table 2 Continued. 
Long-term protection provided by a single-shot vaccine may be achieved by 
regulating the vaccine kinetics (refer to Engineering kinetics of vaccines via polymeric 
methods section) or by non-kinetic approaches which may be achieved by: (1) molecular 
immunostimulants (e.g., nucleic acids, polysaccharides, proteins, polymers) and (2) 
advanced vaccine particles (e.g., nanoparticles, microparticles, virus-like particles) 
(Table 2) [188, 189]. 
6.4.1 Pathogen-associated molecular patterns 
PAMPs are key signatures that healthy innate immune systems are able to 
recognize and build an immune response against. PAMPs can be recognized by both 
specific TLRs as well as NOD-like receptors. For example, each of the following are 
recognized by specific TLRs to enhance immunogenicity: lipopolysaccharides (LPS)s 
(TLR2/4), flagellin (TLR5), unmethylated CpG DNA sequences (TLR9 within 
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endolysosomes) [190], double- (dsRNA; TLR3) and single-stranded RNA (ssRNA; 
TLR7). Of note, unmethylated CpG motifs are known to activate innate immunity by 
triggering the expression of Th1 and pro-inflammatory cytokines [191]. A phase I 
clinical study showed that CpG 7909 (TLR9 ligand) was capable of inducing early and 
intense IgG/IgM responses against meningococcal infection. In another clinical study 
(phase III), the CpG 1018-adjuvanted hepatitis B vaccine (HEPLISAV-B®) induced 
seroprotection [117, 167]. 
6.4.2 Adjuvant action – alum, lipids, and polymers 
Alum has been used since 1926. With the aluminum salt (AS), enhanced 
antibody titres are commonly observed. For example, Leung, et al. reported a 1.8-fold 
increase in the antibody titers after the administration of AS04-adjuvanted 
(monophosphoryl lipid A adsorped onto aluminum salt) bivalent recombinantprotein 
vaccine against human papillomavirus (HPV-16/18, Cervarix®) in comparison to the 
tetravalent HPV-6/11/16/18 vaccine (Gardasil®). Lindemann, et al. showed the licensed 
vaccine FENDrix® (alum-adjuvanted vaccine against Hepatitis B) to improve both 
humoral antibody levels from 10 to264 IU/L) and cell-mediated immune responses 
(Table 2) [118, 151]. Additionally, other adjuvant constructions utilized alum-adsorbed 
TLR ligands, which stimulates the expression of co-stimulatory molecules and 
inflammatory mediators and consequently enhances the immune response. For instance, 
the TLR4 ligand glucopyranosyl lipid/synthetic second-generation lipid (GLA/SLA) was 
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used in the treatment against malaria and induced high IFN-gama response in CD4+ Th1 
cells [169, 171]. Although alum is commonly employed for adjuvanticity, limitations for 
intracellular pathogens have been observed (i.e., Mycobacterium tuberculosis (TB)). 
Furthermore, alum may promote IgE antibody production, thereby sensitizing against 
alum. 
Liposome-adjuvanting examples include: the AS01®-adjuvanted RTS,S 
(Mosquirix®; anti-malaria) and the CAF01®-adjuvanted subunit vaccine H56. 
Greenwood, et al. demonstrated Mosquirix® induced effective immune protection 
within infants and children during a phase III clinical trial. In the screening stage, the 
seropositivity rates for anti-circumsporozoite antibodies was 12.8% and it reached 
99.9% after the 3 doses of the RTS,S/AS01 vaccine [192]. Woodworth, et al. described 
long-lasting immune protection elicited by a fusion protein vaccine adjuvanted with 
CAF01 liposome. Such vaccine methodologies have demonstrated tuberculosis 
immunization by enhancing a specific CD4+ T cell population that localizes within the 
TB-infected lung parenchyma cells [159, 162]. Emulsions have also been 
commercialized as MF59®, AS02®, AS03®, AF03®. The general composition 
comprises triterpenes/triterpenoids, phospholipids, and other surfactants. A recent phase 
I clinical trial for HIV-1 vaccination revealed that subjects that received a gp150 priming 
followed by an antigen-expressing modified vaccinia Ankara (MVA) as a boost induced 
binding antibody responses for 40.5% of all subjects, whereas the gp140/MF59® boost 
induced binding antibody responses in 100% of the subjects [156]. 
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Biopolymers are widely used for medical applications and have been reported to 
have adjuvant action in specific applications. For example, polysaccharide-based 
adjuvants can also improve the immunogenicity of vaccines. Chitosan (CS) is known as 
a mucoadhesive molecule and may have important role in mucosal immunization [82]. 
Sawaengsak, et al. [176, 178] reported nanoparticles of CS combined with tri-
polyphosphate and hemagglutinin (HA) to induce a 2-fold increase in the number of 
splenocytes that secrete IFNg in mice infected with influenza virus when compared with 
an un-adjuvanted HA vaccine. Also, Gordon, et al. [91, 175] reported the inulin-based 
adjuvants (Advax®) to elicit efficient immune response against hepatitis B 
immunization during phase I clinical trial. At least a 4-fold increase in the seroprotection 
and the CD4 T-cell responsiveness was observed for subjects immunized with Advax 
when compared to HBsAg alone. Despite of these example, biopolymer has difficulties 
to control drug release due to its solubility in water. The drug carrier which has higher 
pectin proportion in pectin: high amylose portion ratio as 1:1 shows faster drug release 
than lower pectin portion, 4:1. In 4 hours, higher pectin proportion carrier released 
59.07% of Nimesulide and lower pectin proportion carrier released 79.42% [193]. 
Relatively non-toxic and degradable (i.e., via hydrolysis of esters or amidolysis of 
amides) polymers such as poly(anhydride) (PA), poly-N-isopropyl acrylamide 
(PNIPAAm), and PLGA also find application in vaccines. Tamayo, et al. [194] reported 
the recognition of PA nanoparticles by TLR2/4/5, eliciting CD8+ T cell responses, and 
Th1 polarization in mice. Wafa, et al. [195] showed the polymeric structure affecting the 
intensity of the CD8+ T cell response and was also observed to increase the protective 
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duration. PA nanoparticle-based vaccines were recently employed for immunizing 
against swine influenza within pigs [196] and against H5N1 influenza [197]. Shakya, et 
al. [198] discussed the use of PNiPAAm combined with collagen type II as a polymeric 
adjuvant to reduce the risk of triggering autoimmune responses.  
Several studies describe the enhanced immunogenicity due to the adjuvant 
properties of PLGA in comparison to non-adjuvanted antigen priming for subunit 
vaccines (recommended review article [199]). The size of PLGA particles (i.e. nano or 
microparticle), as well as the monomeric lactide:glycolide ratio played a crucial role in 
modulating immunogenicity [200]. Li, et al. [201] described an increase of Th1 cytokine 
expression (IFN𝛾, IL-17) to their pertussis toxoid vaccine by employing dual-range sized 
particles ranging from 200 to 300 nm and 5 µm with a monomeric ratio of 50:50. Cruz, 
et al. [202] reported an increased T-cell response by employing PLGA nanoparticles 
(50:50 L:G) for encapsulating and delivering a protein vaccine.  
6.5 MANUFACTURING AND ENGINEERING DNA 
Engineering and manufacturing DNA vaccines involves multidisciplinary fields 
such as molecular biology/biochemistry, separation techniques, and material science. A 
GOI can be inserted into a self-replicating organism (bacteria or yeast). A circular 
plasmid DNA (pDNA) is usually used as the DNA cloning vector, which can then be 
extracted from the replicating organism, and can be chemically purified [203]. The 
pDNA can be engineered to be expressed in bacteria (i.e. Escherichia coli (E. coli)) 
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[204] or yeast (i.e. Pichia pastoris) [205, 206] for amplification purposes in bioreactors 
and can also able expressed in mammalian cells for a therapeutic purpose. The major 
components involved within an engineered DNA plasmid are the origin of replication, a 
promoter, and the GOI, and also commonly an antibiotic resistance gene for selection 
[207]. As for E. coli-based plasmid production, the composition of the culture media can 
vary from mineral-containing media to complex mixtures supplemented with yeast 
extracts. After the replication in thebioreactor, bacteria can undergo a lysing process 
through alkaline or thermal treatment, followed by plasmid purification via 
centrifugation and precipitation [208, 209]. This large-scale pDNA production is cost-
effective in comparison to LAV and IV manufacturing processes. A relatively more 
recent advent of minicircles (episomal DNA)/miniplasmids (i.e., P1, P7, F)/ministrings 
[210-215] can potentially be transported more easily through cellular barriers to improve 
bioavailability [211]. 
6.6 SAFETY OF DNA VACCINES 
The scientific community has high expectations for DNA vaccine use because of 1) 
the ability to control the transcribed and translated product, thereby controlling the 
ability of the antigen to not revert to a virulent pathogenic form; 2) the relatively low 
production cost of DNA vaccines; 3) the innate stability of DNA vaccines for storage 
and transportation [216, 217] purposes.  
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Despite the positive outlook, DNA vaccines have low immunogenicity and hence 
require immunostimulants and adjuvants. Also, DNA vaccines could potentially trigger 
autoimmune diseases by eliciting anti-DNA antibody production due to the use of 
prokaryotic DNA vectors (e.g. plasmid DNA). Such vectors may contain unmethylated 
CpG sequences and are recognized as a PAMP by TLR9 [121, 218]. CpG repeats for this 
reason can and have been avoided in a number of commercially available plasmids. 
Minicircle DNA [211, 213, 214, 219, 220] and ministring DNA [221, 222], have been 
reported to have less risk of insertional mutagenesis, since major bacterial DNA is 
removed. 
DNA vaccines may cause indel mutations, and incorporation to the host genome 
depending on the mechanism of delivery. Despite non-viral gene delivery systems being 
safer than viral vectors, insertional mutagenesis risks are not zero, although the risks are 
believed to be lower than everyday random mutations. Today, there is still no licensed 
DNA vaccine for human use [223, 224]. 
In 1989, Gilkeson, et al. [225] associated prokaryotic double-stranded DNA 
(dsDNA) immunization to the development of anti-dsDNA antibodies in mice. In 1994, 
Lilic, et al. [226] described the induction of anti-DNA antibodies after the administration 
of a subunit vaccine against hepatitis B virus (HBV) and more recently Zafrir, et al. 
[227] reported that the HBV vaccine induced an autoimmune syndrome induced by the 
required adjuvants. On the other hand, other studies suggested no direct effect of 
vaccinations to triggering autoimmune diseases [228].  
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The administration of a DNA vaccine exposes the patient to foreign DNA or its 
fragments that could insert into the host’s chromosomal DNA [229]. In the case of 
incorporation into an exon, an insertional mutation or frameshift mutation to occur. Such 
mutations can cause a gene to malfunction or inactivate (i.e. a tumor suppressor gene). 
The insertion of foreign genes in the host genome could lead to constituent expression of 
previously silent bacterial/parasite genes that have been inserted as well. The insertion 
may also increase the probability of rearrangements or breaking. The guidelines for 
industrial production of DNA vaccines published by the FDA recommends that the 
pDNA is more than 80% supercoiled in order to help prevent insertional mutagenesis. It 
has been reported that the FDA recommends integration studies, regardless of the 
delivery method, if there are greater than 10,000 copies of foreign DNA per µg of host 
DNA [230]. 
6.7 STABILITY OF DNA VACCINES 
6.7.1 Environmental stability (non-biological) 
DNA vaccines benefit from not needing such rigorous temperature control, as do 
protein-based vaccines. However, the stability of nucleic acid-based vaccines in dry 
conditions (i.e. storage and transportation) or in aqueous conditions are highly dependent 
on stabilization techniques. Crine, et al. [231] reported the stability of apurinic sequence 
sites to remain undamaged for about 288 to 335 hours at 37 ºC, pH 7.21, and a buffer 
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solution close to physiological media. Karni, et al. [232] investigated the thermal 
degradation rates of pDNA (0.75 µg of pUC19) and found that at 170 ºC in aqueous 
solution, there was complete degradation after 9 minutes. When the pDNA was 
incubated at 200 ºC  in aqueous conditions, no intact pDNA could be found after 20 
seconds. In the case of dried pDNA, the degradation temperature was reported to have a 
lower threshold. They incubated pDNA, pUC19, at every 10 ºC for 5 minutes and 
degradation is started from at 130 ºC and completed around 190 ºC. Also, of note, 
prokaryotic DNA was reported to be more thermally stable than eukaryotic DNA [233]. 
6.7.2 Biologically-relevant stability 
The stability of nucleic acids in the physiological environment depends on 
specific conditions in the intracellular, tissue, and systemic levels. In an in vivo 
environment there is variation in pH (~5-7.45), exposure to various enzymes (i.e., 
nucleases) and reactive oxygen species, as well as the possibility of being epigenetically 
modified or modified by host DNA repair mechanisms [234].  
The development of delivery systems for nucleic acids (e.g. polymeric and lipid 
vectors) which control the nucleic acid’s microenvironment helps maintain the 
molecular stability, as there is a decrease in the degradation rate when in a complexed 
state (i.e. polyplex, lipoplex) versus a free state [235]. For example, the in vivo half-life 
for a non-ionically-complexed DNA is approximately 10 minutes in the extracellular 
environment while the intracellular half-life is longer, close to for 1-4 hours. While 
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being in a complexed state is advantageous in terms of its structural stability, if the DNA 
is excessively complexed then successful transcription will not be as efficient, as the 
plasmid will not be accessible to the transcription machinery [236]. 
Evans et.al. [237] described the relevance of controlling the main mechanisms of 
the DNA degradation (e.g. depurination/b-elimination and free radical oxidation by 
employing chelators and hydroxyl radical scavengers). The use of ethanol and EDTA 
(ethylenediamine tetra-acetic acid) or DTPA (diethylenetriaminepentaacetic acid) in 
DNA-based formulations are associated with enhancing the remaining DNA amount 
from approximately 30% to 70% after a 1-month incubation at 50 ºC. 
Peptide nucleic acid (PNA) are uncharged molecules that demonstrate increased 
resistance against nucleases and RNases in comparison to endogenous nucleic acid, 
which can have benefits for specific gene delivery and DNA vaccine applications. The 
conjugation of PNAs with cell-penetrating peptides (CPP)s can enhance the molecular 
stability and facilitate transfection [238]. In addition to being highly stable, CPP-
conjugated PNAs have improved DNA sequence recognition and induces a higher 
affinity with the lipid membranes because of the peptide backbone [239]. 
Epigenetic modification affects the molecular stability and the genetic expression of 
DNA. Modifications such as DNA methylation are more likely to occur in CpG-enriched 
regions [240] and the methylated regions may subsequently recruit DNA methylated-
binding proteins and histone deacetylases (HDAC)s, which downregulate gene 
expression [241] as the transcriptional machinery cannot access the DNA. 
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6.8 PLASMID DELIVERY 
On a cellular level, transporting highly charged macromolecules, such as DNA, 
across a negatively charged phospholipid bilayer membrane and subsequently through 
the restrictive nuclear enveloped is challenging. More specifically, the main delivery 
barriers of plasmid DNA are as follows: stability (described in the previous section), 
cellular uptake, endolysosomal escape, decomplexation from the carrier, and nuclear 
envelope translocation. The cellular uptake of non-viral gene delivery carriers can be 
uptaken via clathrin-, caveolae-mediated endocytosis, or macropinocytosis (endocytic 
pathways) [242, 243]. Plasmids can be internalized within the nucleus via intranuclear 
injection, direct/indirect nuclear localization signals (i.e. DNA-targeted sequences), and 
encapsulation by the nuclear envelope upon reformation post-mitosis [244]. Plasmids 
can be internalized within the nucleus via intranuclear injection, direct/indirect nuclear 
localization signals (i.e. DNA-targeted sequences), and encapsulation by the nuclear 
envelope upon reformation post-mitosis. 
On a systemic level, eliciting specific antibody subtype responses depends on the 
context of the delivery method. For instance, the Lactobacillus vector against the 
influenza A virus induces a higher survival rate in a murine model through intranasal 
vaccine administration than oral administration [245]. Increased IgA titers were 
measured for the intranasal route for an anti-HIV DNA vaccine, in comparison to the 
intramuscular route after DNA vaccination [246]. IgG2a can be induced greater via an 
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intramuscular vaccine administration; whereas a gene gun method could elicit a greater 
IgG1 antibody response [247]. 
6.8.1 Physical DNA delivery methods 
Electroporation was intended to create transient pores in the plasma membrane of 
host cells to increase the kinetics of plasmid DNA under an electrical field. In a recent 
clinical trial, a DNA vaccine was injected intramuscularly with subsequent 
electroporation [248].  
Another physical method developed by delivering plasmid DNA-adsorbed gold 
nanoparticles using gas-pressurized guns, which also improved the cellular uptake. A 
gene gun has been recently used in preclinical trial in non-human primates to deliver 
DNA vaccine against dengue virus [249]. Choi, et al. [250] compared three different 
delivery methods (intramuscular, intradermal, epidermal inoculation) using plasmid-
coated gold beads through particle-pressurized bombardment Intradermal injection and 
gene-gun show specific IgG antibody responses but not IgA. Despite the induction of 
IgG responses, both the gene gun and intradermal administration methods failed to 
protect mice from a rotavirus infection in this specific example. 
Davtyan, et al. [251] investigated the efficiency of a gene gun-delivery method 
for a DNA epitope vaccine (DepVac) versus an electroporated method (intramuscularly) 
for immunizing against Alzheimer’s disease. They found similar antibody and T cell 
responses in both methods for this specific application.  
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Other physical methods have included physical puncturing of the cells via 
microneedles (impalefection), hydrostatic pressure, squeezing cells in a microfluidic 
chamber (in addition to electroporation) [252], and sonoporation [253].  
6.8.2 Non-viral methods 
Lipids or cationic, amine-containing polymers are often used to complex with 
anionic plasmid macromolecules into nano-sized carriers, which facilitates the cellular 
uptake and inhibits the degradation of the plasmid during trafficking. The number of free 
carriers in the solution is critical to the delivery efficiency and it is typically 
administered in many fold excess. The main challenges for non-viral methods are 
increasing the cellular uptake efficiency, avoiding the endolysosomal degradation, and 
preventing protein unfolding or denaturation during carrier encapsulation [254]. 
Tang, et al. [255] described the delivery of a protein cargo by fusion protein-
containing gold nanoparticle-stabilized capsules directly to the cytosol by membrane 
fusion, which prevented protein degradation in the endolysosome. In the comparison of 
caspase-3 delivery with and without nanoparticle-stabilized capsules(NPSC) to HeLa 
cells, caspase-3 with NPSC shows 72.0% apoptosis of HeLa cells after 1 hour incubation 
while without NPSC shows around 2%. 
Analysis of the cell membrane's interaction with amphiphilic materials has 
demonstrated that adsorption of hydrophobic moieties (i.e. Lipofectamine 
2000®/3000®, lipid-based or a greater number of carbons in the polymer backbone or 
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sidechain) can cause disruption or deformation of the outer layer of the cell membrane, 
and that this disruption can induce endosomal uptake [128, 256, 257]. Therefore, 
promoting cellular uptake is often accomplished using polymers designed to increase the 
interaction between nanoparticles and the cell membrane.[6] 
In regards to the cell specificity, surface modifications can be employed for 
enhancement and structures of the carriers can be screened via high throughput methods 
to discover cell specificity (i.e. healthy versus cancerous using PBAEs) [258].  
After internalization via an endocytic pathway, the plasmid DNA or vaccine 
carrier should efficiently escape from the endolysosome into the cytoplasm in order to 
avoid degradation. Several authors describe a greater endosomal escape using 
polyethyleneimine (PEI) conjugated to the plasmid DNA in order to further enhance the 
“proton sponge effect”, which provoke the endosome to swell and then disrupt [259]. 
This effect occurs due to the buffering capacity of the unprotonated amine groups of the 
PEI structure, creating an imbalance in charge and osmotic pressure across the 
membrane. Thus, there is an influx of Cl- ions and water molecules into the endosome 
[260]. Other escape mechanisms have involved fusogenic peptides, For example, Nakase 
and Futaki [261] suggested the association between PEI and the fusogenic peptide 
GALA on the cationic lipid-coated exosomes, which increased endosomal escape of 
exosomes. Hu, et al. [262-264] developed a DNA vaccine against malignant melanoma 
employing Tat-based fusogenic peptide with PEI-mannose nanoparticles adsorbed in 
microneedles. The use of the Tat-based fusogenic peptide resulted in stronger T-cell 
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responses and enhanced expression of IFN𝛾 e IL-12. This kind of approach can 
potentially be applied for plasmid DNA delivery [151]. 
A  nuclear localization sequence can also be indirectly incorporated in plasmid 
DNA-polymer complexes by using DNA targeting sequence (DTS) [265]. DTS is a 
DNA sequence that can be incorporated in the plasmid DNA and is a binding site for 
transcription factors. After the DNA is separated from the complex, this sequence 
containing the sequence for NLS can be transcribed and translated to allow for improved 
nuclear delivery of the plasmid DNA. A well-known example of DTS is simian virus 40 
(SV40) which has a binding site for NLS-containing transcription factors [235, 266]. 
Thus when SV40 promoter sequence is incorporated in the plasmid DNA of interest, 
improved gene transfection can be observed. 
Extensive reviews recommended for non-viral gene delivery barriers: [267, 268]. 
6.8.3 Viral-like particles 
The viral invasion efficiency can also be achieved through virus-like particles 
(VLP)s, which consist of self-assembled structures of proteins that mimic the viral 
capsid but carry no viral genetic material as well [269]. This approach enables the 
presentation of PAMPs similarly to what a viral pathogen would elicit in the patient’s 
immune system but without risk of contamination, infection, or reversion. The licensed 
vaccines Engerix®, Recombivax®, Gardasil® are examples of successful VLPs 
available in the market. Akache, et al. [270] described the Qb-VLP produced from Qb 
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capsid protein subunits, self-assembled using bacterial RNA, and conjugated with IgE 
peptides for the treatment of asthma and rhinitis. Experiments in mice showed increased 
levels of anti-IgE antibodies, which was enhanced by the TLR7 activation (RNA as an 
intrinsic adjuvant).  This approach enables the presentation of PAMPs similarly to what 
a viral pathogen would elicit in the patient’s immune system but without risk of 
contamination, infection, or reversion. The licensed vaccines Engerix®, Recombivax®, 
Gardasil® are examples of successful VLPs available in the market. Akache, et al.  
described the Qb-VLP produced from Qb capsid protein subunits, self-assembled using 
bacterial RNA, and conjugated with IgE peptides for the treatment of asthma and 
rhinitis. Experiments in mice showed increased levels of anti-IgE antibodies, which was 
enhanced by the TLR7 activation (RNA as an intrinsic adjuvant). 
Recent clinical trials employed VLP for the immunization against HIV-1 (phase 
II, modified vaccinia Ankara expressing HIV-1 VLPs) [271], Chikungunya virus (phase 
I, recombinant E1/E2 structural proteins) [272, 273], influenza A virus (phase I, a Qb-
VLP containing gH1/HA) [274], human papillomavirus L1 (phase III, HPV16/18) [275]. 
6.8.4 Viral methods 
Viruses have been adapting over eons to efficiently delivery nucleic acids. 
Although, there have been many concerns over insertional mutagenesis and the safety 
profile of viral vectors, particular concerns for certain viruses have been alleviated to 
varying degrees; for example, viruses can be engineered to have greater control over 
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tropism [276]. We recommend the following extensive review for further information 
regarding viral gene delivery by Thomas, et al [277]. 
Another cellular uptake pathway for delivery particle is by mimicking the 
conditions of a viral invasion. The viral membrane fusion to the host plasma membrane 
depends on the envelope glycoproteins to overcome the unfavorable energetic barrier 
[278]. Virosomes are produced from the pathogenic virus itself devoid of genetic 
material. The advantage is that the virosomes can easily cross the host plasma membrane 
and deliver the DNA vaccine cargo into the host cell [279]. Leroux-Roels, et al. [280] 
described a phase I clinical trial employing gp41-derived peptide vaccine against HIV-1 
using virosomes. 
6.8.5 Clinical trials 
The research conducted in animal models indicated good immunogenicity to 
DNA vaccine, but the clinical trials indicate a non-trivial translation to human [281]. 
Research has led to several licensed DNA vaccines for veterinary use only (West Nile 
Innovator®, Apex-IHN®, Life Tide-SW5®) [282] while DNA vaccines for human use 
has remained in various phases of clinical trials.  
According to Gene Therapy Clinical Trials Worldwide website by Wiley, the 
majority of gene therapy clinical trials are still in the beginning stages. 57.3% (1409 out 
of 2463) of clinical trials are in phase 1 and this number expectedly decreases with each 
stage; phase 2 and phase 3 are 17.3% and 3.8%, respectively. 
148 
The greatest indication for gene therapy clinical trials is for cancer (64.5%), 
followed by monogenic diseases (10.3%) (i.e., cystic fibrosis and hemophilia) and 
infectious diseases (7.5%). The most common vector used in gene therapy clinical trials 
was the adenovirus, which accounted for 21.4%. Retrovirus and naked/plasmid DNA 
accounted for 18.2% and 17.2%, respectively. 
6.9 CONTROLLING GENE EXPRESSION VIA PLASMID ENGINEERING 
AND GENE CIRCUITS 
The design of the plasmid includes the selection of the DNA insert (gene of interest, 
GOI), the DNA vector, the transformation protocol, and the host organism. The GOI 
chosen must be related to the expression of molecules from pathogenic organism that 
can elicit effective immunoprotective, such as surface bacterial proteins (HBsAg for 
Hepatitis B disease and envelope viral glycoproteins (gp120 for HIV-1 disease) [283-
285]. The replication of plasmid DNA in E. coli-replicated is common for several DNA 
vaccines [286, 287]. Recent technologies suggest that the use of minicircle DNA as non-
viral DNA vehicle may increase therapy biosafety, since bacterial DNA is removed from 
parental plasmid, remaining only the GOI and promoter/terminator sequences [288]. 
Moreover, studies about gene transfer shows that minicircle induce 10-1000-fold 
increase in long-term transgene expression in vivo and in vitro, which can impact 
improve the immunogenicity of the DNA vaccines [289]. 
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In this sense, Deans, et al. proposed a novel mechanism which allows gene 
expression control through inducers attached to genetic circuits [290]. Through the 
optics of the DNA vaccine technology, it would be possible to accurately switch on/off 
the expression of GOIs through molecular controllers, enabling the regulation of the 
immune response intensity and type (cell-mediated/humoral). 
The genetic expression profile depends on stimuli from sources other than the 
prime DNA vaccine, and can be understood by means of the Th1/Th2 balance, enabling 
the fine control of cell-mediated and humoral immune responses. CpG ODNs are 
synthetic oligodeoxynucleotides with great similarity to DNA sequences found in 
prokaryotic genome (unmethylated CpG sites in bacterial genome) and can be 
recognized by TLR9 in the endolysosomes of the host immune cells, inducing Th1-
biased immune response [291, 292]. Recent DNA vaccine studies successfully enhanced 
immunogenicity by including CpG ODNs as booster [293-295]. 
Early studies about the improvement of pDNA transient gene expression (TGE) 
efficiency investigated different combinations of promoter/enhancer for gene expression, 
as well as the TGE efficiency for HIV-1 vaccination [296, 297]. Sun, et al. [298] and Li, 
et al. [299] reported use of posttranslational regulatory elements to improve the 
efficiency of DNA vaccine.  
Codon optimization consists in adapting the DNA sequences between different 
species intending to augment the expression of the GOI. During the plasmid design, low 
frequency eukaryotic codons in the foreigner DNA backbone are identified and replaced 
for high frequency codons, but maintaining the same the respective coded amino acids 
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[300-302]. Recent progresses enhanced immunogenicity in mice and chicken primed 
with codon-optimized DNA vaccine [303-305]. 
Synthetic gene circuits provide tools for accurately controlling gene expression, 
which can be relevant in the development of DNA vaccine [290]. 
Recently synthetic biology has been widely used for developing genetic 
engineering to conduct various developmental and functional studies. As discussed 
previously, gene networks are often used in E.coli and other simple organisms but gene 
networks are increasingly being designed for mammalian cells. Lac operon, for example, 
has been widely used in many gene expression studies where isopropyl β-D-1-
thiogalactopyranoside (IPTG) is used as an inducer to promote gene transcription. The 
timing of the addition of this inducer controls the transcription [306]. Similarly, 
biomaterials have been proposed to be used along with synthetic biology for improved 
control in gene expression in mammalian cells [290]. While biomaterials provide a 3D 
microenvironment for the cells, synthetic biology can be combined with biomaterials to 
have better control over gene expression. Gene circuits in the cells can be incorporated 
in the biomaterial of choice for more control over the inducer. Various biomaterials can 
be designed such that the release of inducers can be controlled. Biomaterials like 
polyethylene glycol (PEG) and PLGA can be used for various applications in the study 
of soft tissues and bone structures, respectively. Gene circuits are designed for different 
applications and to improve transfection efficiency before incorporating the cells with 
gene circuits in the biomaterials. 
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Synthetic biology is used to design gene circuits which is applicable for many 
processes, such as cancer. For example, gene circuit was designed to be used with 
CRISPR technology where two single-nucleotide polymorphisms related to the 
occurrence of colon cancer is detected and cas9 enzyme is used to control the expression 
of target genes [307]. Brophy and Voigt [308] built a gene circuit in E.coli with an anti-
sense promoter placed next to the terminator to study the function of anti-sense promoter 
as a regulator. The same group has also worked on designing computation tools like the 
“DNAplotlib” to visualize the gene circuit outline [309]. Another application in gene 
circuit and synthetic biology is the orthogonal polymerases to independently controlling 
multiple pathways in the same cell [310]. Using multiple activator-chaperone pairs have 
also been observed to improve the orthogonality in gene circuits [311]. Moon, et al. 
[311] used a 4-input AND gate that can control the gene expression of multiple 
pathways at the same time independent of each other employing E.coli. 
6.10 OVERCOMING IMMUNOGENIC ISSUES OF DNA-BASED VACCINES 
One of the suggested solutions is to integrate the plasmid, genes for those cytokines 
such as IL-4 or granulocyte-macrophage colony-stimulating factor (GM-CSF) that 
enhances immune responses or for C3d oligomers as an adjuvant for B-lymphocyte cells. 
Other likely approach may include an ensuing booster immunization with the relating 
antigen as a protein. Concomitantly, several studies assessed the immunogenicity of 
adjuvants inserted in the antigen vector (genetic adjuvant) and expressed by the host 
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organism, prompting a more complex DNA vaccination strategy and merging with the 
gene therapy field. Some studies assessed the immunogenicity of DNA vaccines 
containing chemokine expressing sequences for HIV-1 immunization [180-182]. 
Kalams, et al. [180] reported IL-12 and/or IL-15 to produce safe and immunogenic HIV-
1 Gag DNA vaccine and 2013 the same author evaluated the positive impact of the 
electroporation (EP) delivery methodology for the HIV-1 Gag antigen/IL-12 adjuvant 
plasmid vector both as phase I clinical trial. More recently, there have been studies 
exploring genetic adjuvants against cholera (murine) [184], infectious bursal disease 
(chicken) [186], as well as cancer (murine) [187]. 
6.11 EXAMPLES OF DNA-BASED VACCINE COMMERCIAL SUCCESSES 
According to the DNA vaccine database DNAVaxDB [312], there have been over 
20,000 articles by 2017 indexed in PubMed and google scholar that have been taken to 
study DNA vaccines. However, there has not yet been a licensed DNA vaccine for 
human use so far. Since the gene-based formulation required more safety evaluations 
compared to conventional vaccines (e.g. nucleic acid integration into host chromosomal 
genome), the processes of DNA vaccines for human applications are relatively time 
consuming. While many human DNA vaccines are still being evaluated in clinical trials, 
there have been 4 studies of DNA vaccines that are approved for veterinary applications. 
An overview of approved DNA vaccines for animal models has been reported in several 
articles [313-315]. These vaccines target to different animal species, including horse, 
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salmon, swine and dog model. The earliest approvals were in 2005, West Nile–
Innovator® and Apex-IHN®. These two are prophylactic vaccines for infectious 
diseases, encoding parts of protein of viruses, against West Nile Virus and infectious 
haematopoietic necrosis virus, respectively. In 2008, a single dose of vaccine expressing 
the growth hormone releasing hormone, LifeTide® SW5, was licensed for gene therapy. 
The latest approved one was in 2010, OnceptTM, used for cancer immunotherapy against 
oral melanoma. 
The success of vaccine tests in animal models boosts the investigation and 
investment of human clinical trials. To date, there are currently at least 40 clinical 
interventional trials evaluating human DNA vaccines, according to a quick search with 
“DNA Gene plasmid vaccine” on the Clinical Trials website. Studies under unknown 
status/withdrawn were excluded and studies have been patented/sponsored were then 
summarized in Table 3. The majority of these trials are investigating for infectious 
diseases as prophylactic vaccines, including HIV infection, virus infection, influenza, 
hepatitis B, etc. A variety of trials for potential therapeutic usage as immunotherapy for 
cancer, immunomodulator for asthma/allergy, and gene therapy for chronic infection are 
being evaluated as well. A detailed analysis of clinical trials of gene based prophylactic 
vaccines (including virus vaccine) was reported by Nakayama, et al. in 2015 [316]. 
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Table 3 Selected current DNA vaccines in the progress of Phase I to III clinical 
trials. 
Up to date, most of clinical trials showed no evidence of DNA integration into 
host chromosome and immunologic tolerance. However, poor DNA plasmids 
transfection efficiency resulting in insufficient induction of immune response is possibly 
one of the greatest challenges in current trials. As a result, more trials utilized hybridized 
formulations or higher DNA doses for greater immunogenicity [317]. GOVX-B11, are 
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two components vaccine. It consists of a DNA vaccine used to prime a person’s immune 
response and a recombinant MVA (modified vaccinia Ankara, attenuated vaccine) used 
to boost the primed responses. Their studies were undertaken in HIV infected 
participants on antiretroviral treatment and have been demonstrated that GOVX-B11 is 
capable of eliciting antibodies and T cell response against a heterologous challenge 
[318]. On the other hand, PENNVAX DNA vaccines developed by Inovio 
Pharmaceuticals, currently in phase I progress, utilize the same prime-boost strategy as 
GOVX-B11 by combining a viral vector vaccine. Further, Inovio demonstrated that the 
immune response can be enhanced when delivered via in vivo intradermal 
electroporation of PENNVAX compared to syringe injection [319, 320]. These results 
reveal that the modification of DNA vaccine formulation or delivery approach can 
improve the potency and efficacy of the DNA vaccines in human trials.  
As of 2016, a great deal of second generation vaccines have been licensed and 
released on the market. Some of DNA vaccines have been approved for sale in animal 
health as well (summarized in Table 4). These reports provide evidence on the potential 
and growth of worldwide market for new vaccine technologies. Regarding the feasibility 
of current trials of DNA vaccines, further advancement of the plasmid formulation and 
delivery approaches will be the necessary work for the continued improvement of DNA 
platform.  
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Table 4 Recent licensed protein and DNA vaccine therapies. (data extracted from 
2001 to 2017) 
6.12 CONCLUSION AND FUTURE DIRECTIONS 
The present article compiled recent advancements on nucleic acid- and protein-
based vaccines from the point of view of the biomedical engineering by bringing 
together basic, applied, and translational knowledge in order to point future trends to 
addressing global vaccinology challenges. First of all, the challenges are present in 
several categories such as logistics (i.e. molecular stability, storage and transportation 
conditions, global coverage rates), in vivo barriers (i.e. administration pathways, 
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intracellular/nuclear uptake rates, endosomal escape), and immunological issues (i.e. 
Th1/Th2 balance, effective seroconversion, adjuvancity, gene expression). 
In this sense, the development of nuclei acid-based vaccines combined with the 
encapsulation with biocompatible and biodegradable polymers can enable a 
sophisticated solution in short-term. Even though there still no DNA vaccine for human 
use in the market, this scenario may change. The development of gene circuits creates a 
new horizon for developing novel DNA constructs with enhanced gene stability and 
precise expression control. Furthermore, personalized drugs designed to fit the patient’s 
specific genetic characteristics could be also developed. 
Regarding the protein-based vaccines, there is an immediate need for long-term 
single injection vaccines for both bolus and sustained antigen release kinetics. Such 
technology can reduce the number of administration necessary to accomplish a multiple 
vaccination regimen (e.g. hepatitis B require three doses at 0, 3, and 6 months) [321] and 
can dramatically change the vaccination scenario for both developed and developing 
countries. Thus, it is necessary to develop a protective carrier to prevent the antigen to 
degrade in the in vivo hydrolytic and enzymatic environment. The development of 
PLGA-, PCL-, PBAE-based microparticles for antigen delivery will continue promising 
solutions in the next few years. However, further studies are needed about the antigen 
stabilization inside the carrier. 
Freeze-drying or lyophilization is a well-known technique to improve storage 
and transportation properties of vaccines by removing water from the delivery 
nano/microparticle but maintaining the bioactivity and the conformation of encapsulated 
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antigens. In major antigen encapsulation methods (e.g. single-, double-emulsion, spray 
drying, solvent extraction), water remains inside the particle core even after the 
lyophilization, which continually exposes the antigen to hydrolytic degradation [322, 
323]. Some studies reported the effect of time and thermal conditions of the secondary 
drying step of lyophilization over the antigen stability [324, 325].  
Another way to improve water control for antigen stability is by using cryo-
protectants, which are already widely used in the food and drug industry to enhance the 
lifespan of the products. In vaccinology, sugar cryo-protectants are essential to preserve 
the antigen structure due to hygroscopic properties, avoiding protein aggregation and 
degradation during lyophilization [25, 326, 327]. A recent study showed trehalose to 
consistently preserve the structure and function of protein in exosome after several 
freeze-thaw cycles [328]. Also, the adequate antigen/cryo-protectant proportion can 
optimize the antigen preservation for long-term delivery, even though the correlation 
between the cryo-protectant concentration and the stability is not yet completely 
understood [329]. 
Another challenge for the current vaccinology is to overcome the poor 
immunogenicity of subunit vaccine, especially for DNA-based vaccines. Despite the 
commercial successes of DNA vaccines for veterinary use, no version has been licensed 
for human use. A deeper knowledge about the immune system and the development of 
technologies that offer accurate gene expression control can overcome the 
immunogenicity and biosafety problems regarding DNA vaccines. 
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Studies of Deans, et al. [290] advanced to the control of transgene expression by 
the construction of gene circuits with a precise switch on/off mechanism. The production 
of a gene circuit employed suppressors to inhibiting the expression of the GOI. The 
precise control of gene expression considerably reduces the risks of (1) expression of 
prokaryotic genes from the GOI, (2) eliciting anti-DNA antibodies, (3) foreign DNA 
integration to the host genome, (4) indel mutations. 
Equally important to the need for precise gene expression is the choice for the 
adequate GOI in the plasmid construction to efficiently elicit the immune system. 
Mutations in pathogenic microorganisms leads a constantly renewing pool of circulating 
PAMPs, which creates an enormous challenge to the immune systems to recognize and 
elicit an immune response. Conserved sequences are reliable targets for DNA vaccine 
applications since it allows the expression of more recognizable PAMPs by the host 
immune system regardless of the evolutionary virus or bacterial mutation. Zheng, et al. 
described influenza virus matrix protein M1/M2 and nucleoprotein to be highly 
conserved and important for developing a universal influenza antigen. Yang, et al. [330] 
showed HIV-1 short conserved sequences of Nef, Gag, and Env (i.e. from 43 to 86 
amino acids) to be highly immunogenic [18]. 
Addressing the current challenges of vaccination demands the knowledge of diverse 
fields such as physics, chemistry, physiology, immunology, microbiology, computer 
science. In this context, biomedical engineering has a crucial role in enabling efficient 
interdisciplinary communication for streamlining technology translation from 
advancements from the basic sciences. 
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7 CONCLUSIONS AND FUTURE WORK 
7.1 ENCAPSULATION OF ANTIGEN WITHIN THE CONTEXT OF THE 
MICROBUBBLES 
We quantified antigen stability in aqueous solutions as the positive control (gold 
standard of what we could potentially achieve; dry environment with optimized cryo-
protectant concentration, 0.5 M trehalose, at three different temperatures in section 5.1) 
and also the negative control (in PBS at varying temperatures) and also. Since the 
microbubble is fabricated mainly for vaccine depots (subcutaneous injection or possibly 
intranasal embedding for mucosal delivery), the stability of both antigens HIV-1 
gp120/41 and HBsAg ayw in the microbubble need to be quantified in the presence of 
various trehalose concentrations at temperature in time.  
Antigen wi injected into the microbubble as same method that we inject BSA-dye 
conjugates. Because we analyzed the optimized trehalose concentrations, according to 
our experiment on day 4, the microbubble can be opened on day 4 and day 14 we can 
subsequently analyze the remaining functionality using ELISA to understand the 
decrease in functionality of the antigens within the microbubbbles in time.  
We expect the antigen functionality will be better than in the aqueous solution 
without trehalose, but less than dry phase with trehalose. Because we suspect that 
aqueous phase in the drug is not fully evaporated during the lyophilization process. To 
avoid this, we will vent the inside of microbubble by connecting the venting tube 
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directly to the microbubble (Figure 43) and subsequently anneal the polymer in a 
localized manner post-lyophilization. This venting system allows to improve the antigen 
stability. This stability is critical for successfully immunize our bodies.   
Figure 43. The automated system of microbubble formating using a venting will 
further improve the prevention of hydrolysis within our microbubbles.  
7.2 MULTI-LAYERED MICROBUBBLES 
As a vaccine depot, the microbubbles are required to release drug at different dates 
for the auto-boosting application. To enable different release times, the microbubbles 
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were formed using different MW and different shell thicknesses. The bolus released at 
different time points as was confirmed by the release study of BSA-dye conjugates. 
Figure 44 Multi-layered microbubbles which be formed by multiple injections of 
phase-separating polymers in the middle of the microbubble before curing. 
The major drawback of this microbubble is that patients need to inject same 
number of microbubbles that would result in a human dose to complete the vaccination 
regimen. We may need a few or even dozens of microbubbles which will be painful (we 
are endeavoring to miniaturize the microbubbles to the extent possible). Perhaps a 
topical pain reliever could be applied prior to injection of the microbubbles but this 
would increase the cost of the therapy which is not ideal from a translational standpoint. 
Future work will explore multi-layered microbubbles. Each layer has different MW or 
different polymers which will help catering the microbubbles to required vaccines 
schedules. This could be accomplished by injecting multiple phase separating polymers 
(within organic solvents, Figure 44) in the middle of the microbubble sequentially 
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before curing. Using phase-separating polymers to achieve a wall with multiple 
degradation properties would be useful for modulating the release kinetics so that we can 
target any vaccine schedule required.  
The release study (section 4.2) has shown the drug attached on the surface of 
microbubble released on day 2. This drug was dissolved in 10% CMC due to the failure 
of injection and it was adsorbed to the microbubble surface due to a partitioning effect 
during the curing stage and the likely the initial phases of lyophilization. These surface 
coating entities could be used for combinatorial therapies (likely not applicable for 
protein-based antigen) involving various small molecules. The reason why the model 
antigen had favorable partitioning effect into the organic solvent was likely because of 
the conjugated fluorescence dye. This would need to be further investigated as to what 
entities will be able to partition into the outer portion of the microbubbles, if we decide 
to use this as a tool (i.e., an initial bolus of vaccine rather than within the fluid (i.e., 3% 
CMC) that would be helping push the microbubble through the needle during the 
subcutaneous injection phase (or possibly intramuscular if required, or intranasal 
embedding). 
We could also in the future deliver multiple types of microbubbles which would 
collectively result in the vaccine schedule required if there are limitations in obtaining 
more than 1 auto-boosting dose per microbubble. 
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7.3 MINIMIZING THE DIAMETER OF THE MICROBUBBLES FOR 
IMPROVING INJECTABILITY 
 
In section 3.6, we controlled the size of the microbubble by controlling the syringe 
pump rate. The minimum size was 325 µm with 0.005 µL/sec. For intramuscular 
injection, 22-25 G needles are used for viscous solutions. It means only less than 711 µm 
of microbubble can be delivered through intramuscular injection. For subcutaneous 
applications, it would be ideal to be able to achieve injection via a 24 G needle. 
Therefore, further optimization of the microbubble diameter is necessary to deliver the 
microbubble and also reduce pain or required pain analgesics prior to microbubble 
injection.  
In this work, the microbubble diameter was close to 1 mm as the SEM images 
indicated. The reason for this bigger microbubble diameters is because injection of the 
drug cannot be visualized with bare eyes. As the automation of this system is realized, 
we will be able to miniaturize the diameter without the need for visualization as we are 
no longer would be manually inserting the cargo within the microbubbles. We could 
observe the drug injection, however, by installing a camera inside of the system’s 
container used for lyophilization. To make smaller size of microbubbles, we would 
likely need to use the syringe pump rate which is slower than 0.5 µL/sec or be able to 
cause the micromotors to move translationally faster than the manufacturer’s set rate.  
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